[{"text": "Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX\u00ae2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio Anavex Life Sciences Corp. Mon, Jan 27, 2025, 3:30 PM 5 min read In This Article: AVXL -6.80% Anavex Life Sciences Corp. NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled \u201cA2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF\u201d from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818. This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX\u00ae2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease and other disorders. Anavex\u2019s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX\u00ae2-73 (blarcamesine) patent portfolio, which includes several U.S. Patents, including U.S. Patent Nos. 10,413,519; 10,966,952; 11,661,405; and 11,498,908. \u201cThe issuance of this U.S. Patent again showcases our expertise in identifying and pursuing novel therapeutic forms and formulations that are rooted in science,\u201d said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. He further added: \u201cWe believe the unique properties of the dihydrogen phosphate crystals make it possible in addition to convenient once daily oral dosing to also deliver the active (ANAVEX\u00ae2-73 freebase) in transdermal patches, which could simplify further the administration and boost patients\u2019 compliance. As such, we believe that the addition of the dihydrogen phosphate crystals to our platform could greatly benefit the patients at large.\u201d About Crystal Forms Crystal polymorphism is a unique phenomenon related to chiral compounds, wherein the compounds may crystallize into different crystal structures or crystal forms under different conditions and/or processes. Specifically for pharmaceuticals, polymorphic forms of drug substances \u2018exist in different crystalline forms which differ in their physical properties\u2019. 1 These property differences may result in direct medical implications, such as ease of formulation, increased efficacy, and reduced side effects. For example, the widely used analgesic drug, acetaminophen has three polymorphic forms, I, II, and III, among which only Form I is made into commercial dosage forms as the other two forms are either meta-stable or unstable. 2 Nonetheless, uncovering an optimal crystal form is NOT an easy or straightforward task, because there are so many variables and possibilities involved, and chance of success lies heavily on the researcher\u2019s experience and insights into the compounds in question. Both ANAVEX\u00ae2-73 (blarcamesine) and ANAVEX\u00ae19-144 have the potential to form different crystal forms. Through its deep understanding and abundance experience with these two compounds, Anavex was successful in discovering crystal forms of ANAVEX\u00ae2-73 (blarcamesine) and ANAVEX\u00ae19-144 that have advantageous physiochemical and/or pharmacological properties. Story Continues This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX\u00ae2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX\u00ae2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX\u00ae2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae2-73 for the treatment of Parkinson's disease. We believe that ANAVEX\u00ae3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX\u00ae3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn . Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com 1 ICH HARMONISED TRIPARTITE GUIDELINE, SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A, Current Step 4 version dated 6 October 1999, page 8. 2 Lee E.H., \u201cA practical guide to pharmaceutical polymorph screening & selection,\u201d Asian Journal of Pharmaceutical Sciences, Vol 9, Issue 4, August 2014, Pages 163-175. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-27T12:30:00+00:00", "sentiment": {"score": 0.26716396398842335, "confidence": 0.2757323682308197, "probabilities": {"positive": 0.2757323682308197, "negative": 0.008568404242396355, "neutral": 0.7156992554664612}}, "embedding": [-0.16008320450782776, -0.2264828383922577, 0.021289823576807976, -0.1636204719543457, -0.042145226150751114, 0.009385168552398682, 0.07809346169233322, 0.2170243263244629, 0.06505066156387329, 0.13295112550258636, -0.12678775191307068, 0.12972398102283478, 0.03173433244228363, 0.12657655775547028, -0.11552895605564117, 0.1133943721652031, -0.083922378718853, -0.006825506687164307, 0.061167024075984955, 0.1914743185043335, 0.22728028893470764, 0.024917684495449066, 0.02674112096428871, 0.039174094796180725, -0.044244181364774704, 0.1934370994567871, -0.003625387791544199, -0.080251544713974, -0.0799439325928688, -0.02367420867085457, 0.07695260643959045, 0.17420457303524017, 0.07101668417453766, -0.1988607943058014, 0.06950750946998596, 0.00405404157936573, -0.15337005257606506, -0.006952403113245964, -0.13350340723991394, -0.03754885867238045, -0.025571051985025406, -0.060402289032936096, -0.09584541618824005, 0.14214524626731873, -0.005841516889631748, -0.1352739781141281, 0.028221717104315758, -0.05327557027339935, 0.13193868100643158, 0.14351440966129303, -0.1489688754081726, -0.11455966532230377, 0.0881120041012764, 0.05285361409187317, -0.03523321449756622, 0.07263244688510895, -0.14667043089866638, -0.017824649810791016, -0.07266857475042343, 0.03559056296944618, 0.03477217257022858, -0.040049124509096146, 0.07401864975690842, -0.0723002701997757, 0.1120326966047287, 0.08485164493322372, 0.03518328815698624, -0.13516873121261597, -0.04127021133899689, -0.017555134370923042, 0.006897108629345894, -0.007171706296503544, -0.010503018274903297, 0.19163160026073456, -0.0039388942532241344, 0.18768668174743652, 0.13854913413524628, 0.007572870701551437, -0.029408767819404602, -0.25847139954566956, 0.07291655242443085, 0.09625892341136932, 0.11699213832616806, 0.034512389451265335, 0.08590114116668701, 0.08255191892385483, 0.047713443636894226, 0.10674227774143219, 0.16669650375843048, -0.06877929717302322, 0.05678379908204079, -0.006458839401602745, -0.04197544604539871, -0.11719586700201035, -0.002271302044391632, -0.10667868703603745, -0.040798887610435486, 0.1888694167137146, 0.06983809173107147, 0.038832247257232666, 0.07020363211631775, -0.002902309177443385, -0.18523532152175903, -0.05731789022684097, 0.00811209436506033, -0.055740177631378174, 0.03978240117430687, -0.09804235398769379, 0.12891614437103271, 0.04968811571598053, -0.09892670810222626, 0.11955475807189941, 0.06105408817529678, 0.03594721853733063, -0.12566620111465454, 0.09790757298469543, -0.04208172857761383, -0.04495026916265488, 0.18362796306610107, -0.10811842978000641, 0.11037515103816986, -0.09832671284675598, 0.027119852602481842, -0.09191107749938965, 0.09957467019557953, -0.024413157254457474, -0.1569558084011078, 6.698690474695119e-33, -0.12071996182203293, 0.09435319900512695, 0.047740958631038666, 0.19613361358642578, -0.090211421251297, -0.024865124374628067, 0.09777035564184189, -0.013258818536996841, -0.13357065618038177, -0.22676518559455872, -0.2269795536994934, 0.03449933975934982, 0.044135984033346176, 0.18540726602077484, -0.031167250126600266, -0.018062815070152283, -0.04650816321372986, -0.012545492500066757, 0.13864751160144806, -0.07645827531814575, -0.0012476388365030289, 0.03860514611005783, -0.05725913867354393, 0.13340117037296295, -0.12975648045539856, -0.01180624682456255, -0.06210331246256828, 0.04275578260421753, 0.10770255327224731, -0.0012214640155434608, 0.042027294635772705, 0.07110060006380081, -0.03598553687334061, -0.07751268148422241, -0.13850876688957214, 0.0037170350551605225, -0.12123619019985199, -0.11722876131534576, 0.030974669381976128, -0.042926348745822906, 0.12104491889476776, 0.17006048560142517, -0.05564598739147186, -0.020919330418109894, 0.037774719297885895, -0.01568438671529293, -0.08019636571407318, 0.09516814351081848, 0.050367508083581924, -0.10591871291399002, 0.062062934041023254, 0.12285026907920837, -0.022200390696525574, -0.14904579520225525, -0.04446158558130264, -0.05357823148369789, -0.21831312775611877, -0.030656345188617706, 0.1931493878364563, 0.16699376702308655, -0.0337834469974041, 0.10408586263656616, -0.0033355657942593098, 0.0999508798122406, -0.055470068007707596, 0.1383976936340332, 0.08069434762001038, -0.12528575956821442, -0.02668321691453457, 0.07621687650680542, 0.06786599010229111, 0.015342832542955875, 0.10118880867958069, -0.03905351459980011, 0.07951639592647552, -0.109407439827919, 0.08031448721885681, -0.03538961708545685, -0.053186625242233276, -0.09192439913749695, -0.07874692976474762, 0.007932888343930244, -0.08640578389167786, 0.09975610673427582, -0.11093933135271072, -0.058096993714571, 0.05301693081855774, 0.07317919284105301, -0.12661606073379517, -0.04328667372465134, 0.08118928968906403, -0.20366117358207703, -0.13432572782039642, 0.051236629486083984, -0.05797490105032921, -6.532226515623267e-33, -0.15493547916412354, -0.08185750246047974, -0.11838459968566895, -0.0028578853234648705, -0.01000500749796629, 0.06702636182308197, 0.14920291304588318, 0.044994011521339417, 0.10066930949687958, -0.19919949769973755, 0.2630985975265503, 0.03833581879734993, 0.01660291664302349, 0.009771890006959438, -0.04493407905101776, 0.043198950588703156, -0.07692286372184753, -0.06352001428604126, -0.05045907944440842, -0.00047268252819776535, 0.015227198600769043, 0.2922818660736084, -0.06438988447189331, 0.13792836666107178, 0.1303400695323944, 0.08631289005279541, 0.013159222900867462, 0.038902804255485535, 0.06652919203042984, 0.04421420395374298, -0.13393571972846985, 0.08152781426906586, -0.2921944260597229, 0.03038315288722515, -0.052503615617752075, -0.03760092705488205, 0.03469002619385719, -0.304812490940094, -0.08987796306610107, -0.1017599105834961, 0.0057684737257659435, 0.0580863319337368, 0.030795583501458168, -0.018995843827724457, 0.06967377662658691, -0.031860437244176865, 0.00010718777775764465, -0.02834119275212288, 0.09405104070901871, -0.011222174391150475, 0.009586592204868793, -0.1247880756855011, 0.033813539892435074, -0.08676035702228546, -0.006456442177295685, 0.02256672829389572, -0.08230260014533997, -0.043648794293403625, 0.026166269555687904, 0.002452777000144124, 0.037645742297172546, 0.10105752944946289, 0.0043602315708994865, -0.09177961945533752, 0.033741679042577744, 0.1101280003786087, 0.1204776018857956, 0.08792905509471893, -0.004837401211261749, -0.15491518378257751, 0.05887197330594063, 0.07177317142486572, 0.055126920342445374, 0.032143011689186096, 0.06023915112018585, 0.06241561472415924, 0.055668823421001434, -0.08898386359214783, -0.19422897696495056, -0.0770302265882492, -0.04603661224246025, 0.03471753001213074, -0.037876904010772705, 0.0546659454703331, 0.05643010511994362, 0.002651283983141184, -0.05774734169244766, -0.04807230457663536, -0.05248761177062988, 0.009407507255673409, -0.04093081131577492, -0.13487859070301056, -0.12799793481826782, 0.20522639155387878, 0.09400546550750732, -9.980233528494864e-08, 0.2137966752052307, -0.10419422388076782, 0.04238229990005493, -0.13248804211616516, 0.03519761934876442, -0.023972038179636, 0.0038092939648777246, 0.0662730485200882, -0.022908274084329605, 0.03855530917644501, 0.08182010799646378, 0.12127935141324997, -0.04425783082842827, 0.07463255524635315, -0.11853556334972382, 0.07126407325267792, -0.09667892754077911, 0.040981534868478775, -0.12848107516765594, -0.1220395565032959, -0.10594232380390167, 0.03501671925187111, -0.007713692262768745, -0.05621969699859619, 0.03659793734550476, -0.08588865399360657, 0.06949740648269653, -0.11477884650230408, 0.03122284635901451, -0.09148582816123962, -0.018334152176976204, 0.02029881626367569, 0.13180790841579437, 0.0751916766166687, 0.005680606700479984, -0.170393168926239, -0.004096276126801968, 0.1955055594444275, 0.00861534383147955, 0.04808304086327553, -0.04512094706296921, -0.10170231759548187, -0.05169598385691643, 0.028048943728208542, 0.018233831971883774, -0.013690028339624405, -0.19795721769332886, -0.021991387009620667, 0.0802886039018631, 0.021401021629571915, 0.0637875497341156, 0.045555587857961655, -0.018568746745586395, -0.12828974425792694, -0.1301899254322052, 0.12289810180664062, -0.11525420844554901, -0.11462569236755371, 0.10636518895626068, -0.19779270887374878, 0.07130551338195801, -0.08093144744634628, 0.2548155188560486, 0.05472652241587639], "changes": {"1wk": -5.60080706876633}}, {"text": "Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why Zacks Equity Research Fri, Jan 24, 2025, 6:56 PM 5 min read In This Article: AVXL -6.80% Shares of Anavex Life Sciences AVXL, a clinical-stage biotech making medicines to treat central nervous system (CNS) diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes. Anavex Life Sciences\u2019 clinical developmental pipeline includes two candidates, ANAVEX 2-73 (blarcamesine) and ANAVEX 3-71. Both these candidates are being developed in separate studies across various stages of development to treat a plethora of CNS indications like Alzheimer\u2019s disease (AD), Parkinson\u2019s disease and schizophrenia, among others. Both these candidates have been developed leveraging Anavex Life Sciences\u2019 proprietary SIGMACEPTOR\u00a0Discovery Platform, which produces small molecule drug candidates with unique mechanisms of action. AVXL shares have rallied 53.6% in the past year against the industry\u2019s 12.4% decline. Zacks Investment Research Image Source: Zacks Investment Research Upbeat Initial Data From AVXL\u2019s Schizophrenia Study In October 2024, Anavex Life Sciences reported positive initial biomarker results from Part A of an ongoing mid-stage study of ANAVEX 3-71 for schizophrenia. This multiple ascending dose portion of the phase II ANAVEX 3-71-SZ-001 study, evaluated two oral, daily doses of the candidate (90 mg or 180 mg) in 16 patients for 10 days. Per the preliminary data readout, treatment with the candidate demonstrated a dose-dependent effect on two key electroencephalography (EEG) biomarkers in schizophrenia patients, which were more pronounced in the higher dose group. The two concerned EEG biomarkers correlate with positive, negative and cognitive symptoms of schizophrenia, and are typically found in reduced levels in patients. Improvements in these biomarkers potentially lead to reduced auditory hallucinations, improved executive function and working memory, and reduced irritability and anxiety. Additionally, the candidate was overall well-tolerated with no serious adverse events reported. Anavex believes that ANAVEX 3-71 has the potential to treat all symptom domains of schizophrenia without the side effects of standard-of-care antipsychotics, thereby addressing a significant unmet medical need. Part B of the phase II ANAVEX 3-71-SZ-001 study evaluating the candidate in more schizophrenia patients and over a longer treatment duration is currently ongoing. Top-line safety and efficacy data is expected in the first half of 2025. Anavex Life Sciences is also evaluating ANAVEX 3-71 for other CNS indications like frontotemporal dementia, neurodegenerative diseases and AD. AVXL Files MAA for ANAVEX 2-73 for Alzheimer\u2019s In November 2024, Anavex Life Sciences submitted a marketing authorization application (MAA) for blarcamesine to the EU regulatory body, seeking its approval for treating AD. The filing was accepted for review last month. Story Continues The MAA submission is primarily supported by data from the phase IIb/III study in which blarcamesine showed significant clinical improvement over 48 weeks, with a more than 2-point increase in the ADAS-Cog13 score, the primary endpoint. This indicates greater efficacy compared to approved therapies while also slowing neurodegeneration in early AD patients. Its safety profile eliminates the need for routine MRI monitoring, and its oral administration, combined with its benefits on cognition and neurodegeneration, makes it a convenient and appealing treatment option. The MAA also includes additional safety and efficacy data from the 144-week\u00a0open-label-extension study of the candidate for AD. Anavex believes that the EU presents a strong market for AD treatment, with approximately seven million AD patients \u2014 a figure projected to double by 2030, per the European Brain Council. The company is also currently evaluating blarcamesine for a variety of other CNS indications, including Parkinson\u2019s disease and Rett syndrome. Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. price-consensus-chart | Anavex Life Sciences Corp. Quote AVXL\u2019s Zacks Rank & Other Stocks to Consider Anavex currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and Alnylam Pharmaceuticals ALNY. While CSTL and BMRN currently sporta Zacks Rank #1 (Strong Buy) each, ALNY carries a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, the loss per share for 2025 has improved from $1.84 to $ 1.70. In the past three months, shares of Castle Biosciences have plunged 15.5%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 10.8%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. In the past 30 days, estimates for Alnylam Pharmaceuticals\u2019 2024 loss per share have remained constant at 39 cents. The estimate for 2025 earnings per share is currently pegged at 40 cents. In the past three months, shares of Alnylam Pharmaceuticals have lost 3.3%. ALNY\u2019s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 65.67%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-24T15:56:00+00:00", "sentiment": {"score": 0.8852583169937134, "confidence": 0.9050297737121582, "probabilities": {"positive": 0.9050297737121582, "negative": 0.019771456718444824, "neutral": 0.07519874721765518}}, "embedding": [0.01019936054944992, -0.06997808814048767, 0.005133443977683783, -0.09531964361667633, 0.04165548086166382, 0.0071070436388254166, -0.05452960357069969, 0.16385072469711304, 0.15201151371002197, 0.16067999601364136, -0.16131600737571716, -0.011221757158637047, 0.067393459379673, 0.08499526977539062, -0.07499256730079651, 0.09616180509328842, -0.0988340824842453, -0.00419946014881134, -0.02738126739859581, 0.20027711987495422, 0.01768404431641102, -0.0886831134557724, 0.08723969012498856, 0.05356800556182861, -0.02608545683324337, 0.1691713184118271, -0.043444663286209106, -0.08109114319086075, -0.12748248875141144, -0.0029341569170355797, 0.13660190999507904, 0.13345003128051758, 0.06029908359050751, -0.0681234672665596, -0.017689943313598633, -0.02417859062552452, -0.10301600396633148, 0.027806788682937622, -0.10169167816638947, -0.09832076728343964, -0.02142145484685898, -0.0020625335164368153, -0.05740635469555855, -0.02433740720152855, -0.04868245869874954, -0.21892324090003967, 0.018157800659537315, -0.09268271923065186, 0.09918850660324097, 0.02184784784913063, -0.07124821096658707, -0.09318368136882782, 0.05828177183866501, 0.10666878521442413, -0.13002493977546692, 0.1909485161304474, -0.12791772186756134, -0.008952845819294453, -0.062008086591959, 0.043743375688791275, -0.05827953666448593, -0.04241688922047615, 0.06485076248645782, -0.07150371372699738, 0.09084591269493103, 0.044106293469667435, -0.02967182546854019, -0.15003232657909393, -0.07322123646736145, -0.051382265985012054, -0.04073687270283699, -0.07187400758266449, 0.020059555768966675, 0.11379788815975189, 0.011782245710492134, 0.12639276683330536, 0.19045090675354004, 0.016025688499212265, 0.0869113951921463, -0.22647374868392944, -0.05940442904829979, 0.05274773761630058, 0.10232804715633392, 0.0699068084359169, 0.1495504230260849, 0.05680425092577934, 0.06567414104938507, 0.15431877970695496, 0.045013677328825, 0.06995868682861328, 0.050220027565956116, -0.06613411009311676, 0.007665527053177357, -0.07753776013851166, 0.0999813973903656, -0.04757138341665268, -0.12310648709535599, 0.14395415782928467, 0.006138834170997143, 0.001830199733376503, 0.08832941949367523, 0.01990305446088314, -0.016764767467975616, -0.053877949714660645, -0.07426737248897552, 0.035833217203617096, 0.113174207508564, -0.12377484887838364, 0.04470067471265793, 0.008912311866879463, -0.09766733646392822, -0.013802004978060722, 0.035269010812044144, 0.07130701839923859, -0.06330511718988419, 0.1521223932504654, -0.08424727618694305, -0.005712886340916157, 0.2010999470949173, 0.011254396289587021, 0.1778387725353241, -0.028887581080198288, 0.0911916121840477, -0.04376250505447388, 0.14451634883880615, 0.1141192615032196, -0.09285308420658112, 1.432149436392124e-32, -0.16860534250736237, -0.00043630716390907764, -0.010572033002972603, 0.1127893254160881, -0.09023767709732056, 0.016277965158224106, 0.05726804584264755, -0.008234335109591484, 0.0223830696195364, -0.15028142929077148, -0.14682184159755707, 0.059129610657691956, 0.04624120891094208, 0.1983814537525177, -0.03630700707435608, -0.010531529784202576, -0.01810288429260254, -0.03877962380647659, -0.01087743416428566, -0.05581507086753845, 0.03880813345313072, -0.05705752596259117, -0.0034019099548459053, 0.06566774845123291, 0.008919527754187584, -0.11162860691547394, -0.09322992712259293, 0.1243399828672409, -0.01620093174278736, -0.008434302173554897, -0.08584409952163696, 0.034167610108852386, -0.017278803512454033, -0.0653878003358841, -0.13508214056491852, 0.08354373276233673, 0.07648193836212158, -0.03925646096467972, 0.03751703351736069, 0.09693177789449692, 0.08344036340713501, 0.10525256395339966, -0.06867405772209167, 0.014755752868950367, -0.05460305139422417, 0.03406275063753128, -0.1083761602640152, -0.03160020709037781, -0.00899989902973175, -0.010042771697044373, 0.0037434957921504974, -0.11148647218942642, -0.005055643618106842, -0.0514393150806427, -0.02164674922823906, 0.049867384135723114, -0.11036941409111023, -0.08715396374464035, 0.17498359084129333, -0.001608302816748619, 0.061744578182697296, 0.08243966102600098, 0.04919372871518135, 0.08362139016389847, 0.04351771995425224, 0.07719800621271133, 0.11200543493032455, -0.09768883883953094, -0.11174698919057846, 0.09605847299098969, -0.025349991396069527, 0.056847184896469116, 0.16946281492710114, 0.024892250075936317, 0.11847704648971558, -0.09196759760379791, -0.06537269055843353, 0.00903404876589775, 0.0012486102059483528, -0.008942170068621635, 0.025515088811516762, -0.11748577654361725, -0.11324058473110199, 0.11981786787509918, 0.010100368410348892, -0.049718596041202545, -0.022072508931159973, 0.037764910608530045, -0.1855451464653015, -0.04427553713321686, 0.07269804179668427, -0.07713425159454346, -0.010277314111590385, 0.035117536783218384, -0.11690787971019745, -1.3148001292231229e-32, -0.18418405950069427, 0.017001856118440628, -0.08305612206459045, -0.002363292034715414, -0.02360527589917183, 0.18908190727233887, 0.12554825842380524, -0.048174433410167694, 0.12892509996891022, -0.23612479865550995, 0.09033099561929703, 0.12350140511989594, 0.0634208619594574, -0.05614969879388809, -0.0489501990377903, 0.0034535161685198545, -0.11744384467601776, -0.13948607444763184, 0.027229096740484238, 0.014052505604922771, -0.006437039468437433, 0.1477757841348648, -0.13037237524986267, 0.11968541145324707, 0.11169306933879852, 0.03233877569437027, 0.08842704445123672, 0.055135488510131836, 0.011545464396476746, -0.00749587407335639, -0.12362894415855408, 0.10108846426010132, -0.12871327996253967, -0.0482327863574028, -0.020043008029460907, 0.041628915816545486, 0.0775555893778801, -0.24414032697677612, -0.16644710302352905, -0.17181292176246643, -0.02484518475830555, 0.16683988273143768, 0.033691272139549255, -0.10333289206027985, -0.019310802221298218, 0.00945697259157896, 0.07605299353599548, -0.036326222121715546, 0.03121338039636612, 0.015071914531290531, -0.024986455217003822, -0.07313905656337738, -0.026262817904353142, -0.04679238423705101, -0.012324569746851921, -0.10084874927997589, -0.14261052012443542, -0.03820416331291199, -0.02741974964737892, 0.011832473799586296, -0.017796101048588753, 0.19120487570762634, -0.008528187870979309, -0.021349426358938217, 0.037177614867687225, 0.10884914547204971, 0.03729790449142456, 0.142452210187912, 0.03620368242263794, -0.08191955089569092, -0.028848640620708466, 0.01077091321349144, 0.08928428590297699, 0.09168019890785217, 0.042133621871471405, 0.11641883850097656, -0.002474721521139145, -0.09935781359672546, -0.02445916086435318, -0.10082051157951355, -0.0278826504945755, -0.059487782418727875, -0.06012188643217087, 0.05445142090320587, -0.0299295075237751, 0.004020657390356064, -0.10342442989349365, -0.014818960800766945, 0.022660043090581894, 0.02133803255856037, -0.008025618270039558, -0.12527042627334595, -0.11390459537506104, 0.10904878377914429, -0.03746230527758598, -1.0059457622446644e-07, 0.16754521429538727, -0.12772464752197266, 0.08783558011054993, -0.07501451671123505, 0.02669181302189827, -0.0507926344871521, 0.02454172819852829, 0.019341442734003067, 0.0026566237211227417, 0.03737743943929672, 0.12148576229810715, 0.03433357551693916, -0.06705910712480545, 0.041532017290592194, -0.09116275608539581, -0.0385645255446434, 0.03768671303987503, 0.15862923860549927, -0.06990641355514526, -0.07218355685472488, -0.0745275542140007, 0.07706709951162338, -0.021215438842773438, -0.11350934952497482, 0.1716892272233963, -0.09986105561256409, 0.04018884152173996, 0.046211786568164825, -0.0199873149394989, -0.19675058126449585, -0.09700874239206314, 0.01728607341647148, 0.08486495912075043, 0.047309745103120804, 0.019372373819351196, -0.08510813117027283, -0.017993366345763206, 0.17618443071842194, 0.019119247794151306, 0.10983544588088989, -0.02285538613796234, -0.03765701502561569, -0.024530306458473206, -0.06773261725902557, -0.03686962276697159, -0.028446782380342484, -0.10529160499572754, -0.1435667872428894, 0.11315160989761353, -0.20686185359954834, 0.0568523108959198, 0.11864534020423889, 0.05670018866658211, -0.026864230632781982, -0.14414572715759277, 0.08648756146430969, -0.07253430038690567, -0.03814792260527611, 0.01062547042965889, -0.25071147084236145, 0.019625473767518997, -0.0636778473854065, 0.017161473631858826, 0.02133902907371521], "changes": {"1wk": -11.630117635593127}}, {"text": "Best Momentum Stocks to Buy for January 21st Zacks Equity Research Tue, Jan 21, 2025, 6:00 PM 2 min read In This Article: CDNA +0.09% ALNY +1.19% AVXL -6.80% Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 21st: CareDx, Inc CDNA: This diagnostic solutions company for transplant patients and caregivers has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days. CareDx, Inc. Price and Consensus CareDx, Inc. Price and Consensus CareDx, Inc. price-consensus-chart | CareDx, Inc. Quote CareDx\u2019s shares gained 13.6% over the last six months compared with the S&P 500\u2019s advance of 7.7%. The company possesses a\u00a0Momentum Score\u00a0 of A. CareDx, Inc. Price CareDx, Inc. Price CareDx, Inc. price | CareDx, Inc. Quote Anavex Life Sciences Corp. AVXL: This clinical stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days. Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. price-consensus-chart | Anavex Life Sciences Corp. Quote Anavex\u2019s shares gained 63.3% over the last three months compared with the S&P 500\u2019s advance of 2.4%. The company possesses a\u00a0Momentum Score\u00a0of A. Anavex Life Sciences Corp. Price Anavex Life Sciences Corp. Price Anavex Life Sciences Corp. price | Anavex Life Sciences Corp. Quote Alnylam Pharmaceuticals, Inc. ALNY: This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days. Alnylam Pharmaceuticals, Inc. Price and Consensus Alnylam Pharmaceuticals, Inc. Price and Consensus Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote Alnylam\u2019s shares gained 1.6% over the past month compared with the S&P 500\u2019s advance of 0.4%. The company possesses a\u00a0Momentum Score\u00a0of A. Alnylam Pharmaceuticals, Inc. Price Alnylam Pharmaceuticals, Inc. Price Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote See the full list of top ranked stocks here Learn more about the Momentum score and how it is calculated here . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report CareDx, Inc. (CDNA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-21T15:00:00+00:00", "sentiment": {"score": 0.1907084695994854, "confidence": 0.22246100008487701, "probabilities": {"positive": 0.22246100008487701, "negative": 0.03175253048539162, "neutral": 0.7457864880561829}}, "embedding": [-0.029902024194598198, -0.13590875267982483, -0.012681758031249046, -0.038074929267168045, -0.06708571314811707, -0.07098708301782608, -0.0029714128468185663, 0.09495862573385239, 0.18172961473464966, 0.1083548367023468, -0.0676116943359375, 0.07228001207113266, 0.04342915862798691, -0.033784907311201096, -0.06757254898548126, 0.022018156945705414, -0.005754428915679455, -0.09835442155599594, -0.1925741732120514, 0.1947747766971588, -0.04591847583651543, -0.12301454693078995, 0.07507442682981491, 0.026904085651040077, 0.11268944293260574, 0.0636444091796875, -0.08897951245307922, -0.006744593381881714, -0.11512194573879242, 0.006544364150613546, 0.006858980283141136, 0.07696016877889633, 0.12049105763435364, -0.1362852156162262, -0.011471148580312729, -0.005961589515209198, -0.1136985719203949, 0.036002982407808304, 0.03533409535884857, -0.009801799431443214, -0.06767593324184418, 0.02061399817466736, -0.156954824924469, 0.027181385084986687, -0.06108199059963226, -0.18145719170570374, -0.0055122822523117065, 0.02070523053407669, 0.10512347519397736, 0.07864599674940109, -0.2331002652645111, -0.1345776617527008, 0.010275142267346382, 0.00643266923725605, -0.10531801730394363, 0.10489808022975922, -0.19095835089683533, -0.07883886992931366, 0.05554630607366562, -0.028147049248218536, -0.019929897040128708, 0.03740129619836807, 0.09188544750213623, 0.08266095817089081, 0.049451105296611786, 0.00909952912479639, 0.015989482402801514, -0.005312415771186352, -0.029077278450131416, 0.03779681771993637, 0.08957388997077942, -0.0744415819644928, 0.035639192909002304, 0.09458573162555695, -0.026386570185422897, 0.15179698169231415, 0.11555880308151245, -0.0780184268951416, 0.08416550606489182, -0.09728595614433289, 0.015863118693232536, 0.034085214138031006, -0.028819017112255096, -0.04732271283864975, -0.019915271550416946, -0.025656599551439285, 0.15274667739868164, 0.18084846436977386, 0.025610236451029778, -0.02419053018093109, 0.06354382634162903, 0.015510430559515953, -0.03501089662313461, -0.09216934442520142, 0.110028475522995, 0.01740790158510208, -0.08566936105489731, 0.01944955810904503, -0.038970306515693665, -0.018930263817310333, 0.15832342207431793, 0.014517337083816528, -0.11087779700756073, -0.06980608403682709, -0.08880135416984558, -0.08639921247959137, -0.027233552187681198, -0.003903627395629883, 0.046110425144433975, 0.07359641045331955, -0.12931525707244873, 0.04014042764902115, -0.025348709896206856, -0.043123092502355576, -0.16465938091278076, 0.12606745958328247, -0.059722334146499634, -0.022728940472006798, 0.20269480347633362, 0.016282327473163605, 0.06884652376174927, -0.03188639506697655, 0.051584288477897644, 0.014705121517181396, 0.19690126180648804, 0.055426329374313354, -0.09241722524166107, 1.0343187282512785e-32, -0.07113289088010788, -0.006622593849897385, 0.029114972800016403, -0.058470793068408966, -0.15602177381515503, 0.014204178005456924, 0.14427252113819122, -0.030744390562176704, -0.1495284140110016, -0.10112499445676804, -0.14569514989852905, 0.0642671063542366, -0.059388890862464905, -0.018106907606124878, -0.10486264526844025, -0.12803995609283447, -0.07697543501853943, -0.04198329895734787, -0.02150837332010269, -0.03229954466223717, -0.029403751716017723, 0.03520820662379265, -0.059903424233198166, 0.12023364007472992, -0.06958013772964478, -0.043001700192689896, -0.05978689715266228, 0.041139185428619385, -0.12602412700653076, 0.025375640019774437, -0.018651697784662247, -0.022478073835372925, -0.03562302514910698, -0.1188739687204361, -0.08713562786579132, 0.04663843289017677, -0.08694091439247131, 0.05046270787715912, 0.06802905350923538, -0.024937093257904053, -0.1100580245256424, 0.07565966248512268, -0.08744555711746216, -0.09697295725345612, -0.011783807538449764, 0.10895204544067383, -0.13112767040729523, 0.022970980033278465, 0.08444150537252426, -0.12326164543628693, -0.046715978533029556, 0.006602929439395666, 0.06236322969198227, -0.0015811542980372906, -0.09174033254384995, 0.05887342244386673, -0.008994944393634796, -0.031594544649124146, -0.0031616929918527603, 0.08478064090013504, -0.0781676396727562, 0.10365381836891174, 0.05207688733935356, -0.05450103431940079, -0.07456640899181366, 0.19292518496513367, 0.014603962190449238, -0.006867444608360529, -0.020327184349298477, 0.23998284339904785, -0.0005286308005452156, 0.06060045212507248, 0.18586434423923492, -0.01895453967154026, 0.14949168264865875, 0.02443961799144745, -0.0652662068605423, 0.03432837128639221, -0.03680157661437988, 0.04985912889242172, 0.0794670507311821, -0.016212351620197296, 0.025567108765244484, 0.07174858450889587, 0.035590775310993195, -0.11553341150283813, -0.07777109742164612, 0.09286640584468842, -0.13881799578666687, -0.00502100819721818, 0.11131812632083893, -0.021014738827943802, -0.06226792931556702, 0.15907907485961914, 0.016691895201802254, -1.1821904809233497e-32, -0.0731029212474823, 0.028062032535672188, 0.03906698524951935, 0.033646997064352036, -0.007497050333768129, 0.04131803661584854, 0.029903272166848183, -0.04812754690647125, 0.06941878795623779, -0.0762484222650528, 0.04472662881016731, 0.13672497868537903, -0.062151920050382614, -0.017055019736289978, -0.0294241514056921, 0.08161268383264542, 0.010118278674781322, -0.13022321462631226, 0.01681469939649105, -0.03184298798441887, -0.04668491706252098, 0.1731334775686264, -0.11912614852190018, 0.2156154215335846, 0.08645562827587128, 0.07831623405218124, 0.05914399400353432, 0.11478163301944733, 0.16847103834152222, -0.09312717616558075, -0.05795152857899666, 0.06120002269744873, -0.09879551082849503, 0.01218387670814991, -0.022884640842676163, -0.04733256250619888, -0.049067430198192596, -0.08003129065036774, -0.04109524190425873, -0.03371145576238632, 0.09981588274240494, 0.04538832604885101, 0.15936341881752014, -0.0017028190195560455, 0.10696431249380112, -0.0260016992688179, 0.14558735489845276, -0.11845213174819946, 0.07424665987491608, 0.08200179785490036, -0.07637625187635422, 0.058408573269844055, -0.056418150663375854, 0.07881435006856918, 0.008801547810435295, 0.0633542388677597, -0.10140205919742584, 0.028058014810085297, -0.11647731065750122, -0.09096597135066986, 0.042695749551057816, 0.12851357460021973, 0.036489907652139664, 0.04656071960926056, -0.02806997299194336, 0.06803999841213226, -0.02255639061331749, -0.050327420234680176, -0.08033991605043411, -0.10518527776002884, 0.07292842864990234, -0.040120773017406464, 0.011720535345375538, -0.12596797943115234, 0.05377498269081116, 0.1647261381149292, -0.015993284061551094, -0.12820935249328613, -0.07882563769817352, 0.07681639492511749, 0.03690905123949051, 0.07474824786186218, -0.009059897623956203, 0.08074714988470078, -0.10206828266382217, 0.16067174077033997, -0.03893549367785454, -0.09930538386106491, -0.13765579462051392, 0.016145236790180206, -0.06480976939201355, -0.10420962423086166, -0.07013934850692749, -0.0790434181690216, -0.0013267017202451825, -1.0064646005503164e-07, 0.04500482231378555, -0.08640381693840027, 0.042300205677747726, -0.00903712585568428, 0.12815061211585999, -0.04249736666679382, 0.03379128873348236, 0.11969708651304245, 0.07305371761322021, 0.16523504257202148, 0.19483008980751038, 0.00904998742043972, -0.1810760498046875, 0.056656837463378906, -0.17968252301216125, -0.1027461513876915, -0.19891877472400665, 0.036891184747219086, -0.026370633393526077, -0.14910191297531128, -0.11909571290016174, 0.04245629161596298, 1.3590790331363678e-05, -0.02319832146167755, 0.007104136981070042, 0.008710568770766258, -0.05465952679514885, -0.08222337812185287, 0.05764751136302948, 0.007607401814311743, -0.02878875657916069, -0.025892339646816254, 0.04800589755177498, -0.015956256538629532, 0.04532432183623314, -0.03381696343421936, 0.04402964562177658, 0.10174040496349335, 0.06664707511663437, 0.18426728248596191, 0.040028735995292664, -0.005917944014072418, -0.017057912424206734, -0.03902004659175873, 0.0014272332191467285, -0.009899402037262917, -0.09369006007909775, -0.013006552122533321, 0.11645978689193726, -0.24094748497009277, 0.13584230840206146, -0.04313627630472183, -0.06650027632713318, -0.025736961513757706, -0.10058636963367462, 0.05979423224925995, -0.18191654980182648, 0.01557981688529253, -0.07729658484458923, -0.0026813074946403503, 0.012462502345442772, -0.21930110454559326, 0.11637544631958008, 0.11943607032299042], "changes": {"1wk": 0.6091316103424378}}, {"text": "New Strong Buy Stocks for January 21st Zacks Equity Research Tue, Jan 21, 2025, 2:41 PM 1 min read In This Article: ALNY +1.19% CDNA +0.09% AA -3.43% Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: CareDx, Inc CDNA: This diagnostic solutions company for transplant patients and caregivers has seen the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days. CareDx, Inc. Price and Consensus CareDx, Inc. Price and Consensus CareDx, Inc. price-consensus-chart | CareDx, Inc. Quote Alnylam Pharmaceuticals, Inc. ALNY: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days. Alnylam Pharmaceuticals, Inc. Price and Consensus Alnylam Pharmaceuticals, Inc. Price and Consensus Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote ICL Group Ltd ICL: This specialty minerals and chemicals company has seen the Zacks Consensus Estimate for its next year earnings increasing 8.8% over the last 60 days. ICL Group Ltd. Price and Consensus ICL Group Ltd. Price and Consensus ICL Group Ltd. price-consensus-chart | ICL Group Ltd. Quote Anavex Life Sciences Corp. AVXL: This clinical stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days. Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. Price and Consensus Anavex Life Sciences Corp. price-consensus-chart | Anavex Life Sciences Corp. Quote Alcoa Corporation AA: This company that produces and sells bauxite, alumina, and aluminum products has seen the Zacks Consensus Estimate for its current year earnings increasing 21.4% over the last 60 days. Alcoa Price and Consensus Alcoa Price and Consensus Alcoa price-consensus-chart | Alcoa Quote You can see\u00a0the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Alcoa (AA) : Free Stock Analysis Report ICL Group Ltd. (ICL) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report CareDx, Inc. (CDNA) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-21T11:41:00+00:00", "sentiment": {"score": 0.10173206776380539, "confidence": 0.14772365987300873, "probabilities": {"positive": 0.14772365987300873, "negative": 0.04599159210920334, "neutral": 0.8062847256660461}}, "embedding": [-0.13530880212783813, -0.15015451610088348, -0.03114086017012596, 0.028543228283524513, -0.05686560645699501, -0.07441870868206024, -0.04173228144645691, 0.08859428763389587, 0.004015942104160786, 0.08508288860321045, -0.059550367295742035, 0.08427698910236359, 0.05615047737956047, -0.014482508413493633, -0.10129189491271973, 0.1332377791404724, 0.060553066432476044, -0.11771076917648315, -0.20312996208667755, 0.15534453094005585, -0.0005979463458061218, -0.05616510286927223, 0.12147414684295654, 0.03958612307906151, 0.10465805232524872, 0.09059064835309982, -0.09787032008171082, 0.0063208285719156265, -0.13021890819072723, -0.11028346419334412, -0.11032886803150177, 0.09801702201366425, 0.09340664744377136, -0.1085636168718338, -0.03397031128406525, -0.05754665285348892, -0.10389821231365204, 0.02244504913687706, 0.03312092274427414, 0.043340910226106644, -0.02631700225174427, 0.02163647674024105, -0.14410659670829773, -0.027636220678687096, -0.139820396900177, -0.24235126376152039, 0.01666402257978916, 0.04001159965991974, 0.11924661695957184, 0.16457802057266235, -0.20798437297344208, -0.08964300155639648, 0.03324464336037636, 0.059617459774017334, -0.10019805282354355, 0.008138876408338547, -0.22786319255828857, -0.061911195516586304, 0.09596207737922668, 0.023731527850031853, 0.07449966669082642, 0.04885455220937729, 0.05816304683685303, 0.04551900178194046, 0.10398738086223602, -0.032190509140491486, -0.053725067526102066, -0.052199333906173706, -0.08486370742321014, 0.03323409706354141, 0.021715017035603523, -0.11102411150932312, 0.022291865199804306, 0.0934041291475296, -0.008496774360537529, 0.16098135709762573, 0.17284253239631653, -0.1114003136754036, 0.08417715132236481, -0.11337930709123611, 3.0850525945425034e-05, 0.0385146327316761, 0.012585540302097797, -0.08047255873680115, -0.015027336776256561, -0.021812889724969864, 0.09293434023857117, 0.20492735505104065, 0.023416981101036072, -0.0202033594250679, 0.1393740177154541, 0.05692194402217865, -0.0508696585893631, -0.05557321757078171, 0.06470160186290741, -0.017047077417373657, 0.019204746931791306, 0.06699152290821075, -0.09765918552875519, 0.001999419182538986, 0.14880579710006714, 0.03238929808139801, -0.05077671259641647, -0.07930812239646912, -0.07114800810813904, -0.10105042159557343, 0.08279003202915192, -0.0011450834572315216, 0.020404208451509476, 0.060308970510959625, -0.08006434142589569, 0.07598569244146347, -0.04361142963171005, -0.06578158587217331, -0.18143093585968018, 0.12075762450695038, -0.04874059930443764, -0.00456186942756176, 0.15746545791625977, 0.01256986241787672, 0.029145143926143646, -0.004912409465759993, 0.06494378298521042, -0.0005796304903924465, 0.1499161571264267, 0.08754897117614746, -0.06890203803777695, 1.315668231801205e-32, -0.06932540237903595, 0.006699196994304657, -0.007072011008858681, -0.03743309527635574, -0.1054222509264946, 0.007095523178577423, 0.09249387681484222, -0.012107130140066147, -0.1545429825782776, -0.12795379757881165, -0.1468239724636078, 0.11263192445039749, -0.07729852944612503, 0.046502918004989624, -0.08306929469108582, -0.10333867371082306, 0.026972640305757523, -0.0645323097705841, 0.041595589369535446, -0.056572720408439636, -0.016943104565143585, -0.0013618185184895992, -0.10163622349500656, 0.1174013614654541, -0.019646255299448967, -0.013951572589576244, 0.03139851242303848, 0.017005378380417824, -0.16762350499629974, 0.02809053659439087, 0.0020014806650578976, -0.004076835699379444, -0.08398566395044327, -0.10022145509719849, -0.04888211935758591, -0.009433837607502937, -0.10167702287435532, 0.0158491600304842, 0.06209426745772362, -0.0840417742729187, -0.06614413857460022, 0.08319391310214996, -0.1079796701669693, -0.04365910589694977, 0.09447378665208817, 0.10608399659395218, -0.20676669478416443, 0.11217048764228821, 0.06712664663791656, -0.09297339618206024, -0.08634374290704727, 0.06373796612024307, -0.05464540421962738, -0.04096798971295357, -0.11504817008972168, 0.07818867266178131, -0.07279328256845474, -0.05485343188047409, 0.07285786420106888, 0.16444143652915955, -0.054998692125082016, 0.11034377664327621, 0.027117179706692696, -0.07470256835222244, -0.14819607138633728, 0.11598795652389526, 0.012004340067505836, -0.0021949545480310917, -0.05762027949094772, 0.1721060425043106, 0.02139587141573429, 0.046833157539367676, 0.25532668828964233, 0.019924990832805634, 0.13196396827697754, 0.0035069724544882774, 0.012899917550384998, -0.018755614757537842, 0.02857799641788006, 0.019539998844265938, 0.07965916395187378, 0.002458116039633751, 0.058453597128391266, 0.0559617280960083, -0.06073348969221115, -0.04148715361952782, -0.014284176751971245, 0.034364618360996246, -0.06666488200426102, -0.037172529846429825, 0.05783284083008766, -0.04192733019590378, -0.0479307696223259, 0.06803256273269653, 0.021702026948332787, -1.3082108956395885e-32, 0.04572947323322296, -0.043143849819898605, 0.08127869665622711, -0.05289362743496895, -0.03177884221076965, -0.01861313171684742, -0.005892099812626839, 0.031620170921087265, 0.09456074237823486, -0.04962882399559021, 0.15500585734844208, 0.13856589794158936, -0.06913255155086517, -0.08550464361906052, -0.02038276009261608, 0.022798379883170128, -0.01591247320175171, -0.13134106993675232, 0.07111632823944092, -0.028346003964543343, -0.03204575926065445, 0.16673119366168976, -0.13914845883846283, 0.21232250332832336, 0.02149253711104393, -0.010271957144141197, 0.024845603853464127, 0.14353007078170776, 0.14664535224437714, -0.04966254532337189, -0.07747429609298706, 0.0381854884326458, -0.11599721759557724, 0.08825577050447464, -0.044874198734760284, -0.0167552437633276, -0.006465703248977661, -0.117850162088871, -0.065165214240551, 0.006772033404558897, 0.1047438532114029, -0.00969944428652525, 0.006525859236717224, -0.04010775312781334, 0.14301282167434692, 0.0466797761619091, 0.11248505860567093, -0.08087094128131866, 0.08462460339069366, 0.03334997966885567, 0.023481138050556183, 0.09902296960353851, -0.04650477319955826, 0.0544857531785965, 0.050795018672943115, 0.06313800811767578, -0.060919053852558136, -0.013142856769263744, -0.10214811563491821, -0.06390709429979324, 0.01513964869081974, 0.19692419469356537, 0.07388782501220703, 0.03061961941421032, 0.006068464368581772, 0.07854300737380981, -0.03336566686630249, -0.031331971287727356, -0.030049171298742294, -0.0686531737446785, 0.03441096842288971, -0.08751446008682251, 0.00030634738504886627, -0.13272689282894135, 0.003942966926842928, 0.11147873103618622, 0.002378295175731182, -0.15495425462722778, -0.16052131354808807, -0.009419582784175873, 0.05211494117975235, 0.08112907409667969, 0.04429732635617256, 0.05611357092857361, -0.03252909705042839, 0.11613456159830093, 0.03470413014292717, -0.031165359541773796, -0.11617562174797058, 0.07482688874006271, -0.07053060829639435, -0.16344653069972992, -0.16024164855480194, 0.03331557661294937, 0.020817257463932037, -1.0020636409535655e-07, 0.018218664452433586, -0.02598380669951439, 0.051678139716386795, -0.04630160331726074, 0.18408414721488953, -0.004429918713867664, 0.005420260597020388, 0.1064547598361969, 0.10523174703121185, 0.13908493518829346, 0.12203359603881836, 0.008035138249397278, -0.1703093945980072, 0.046145662665367126, -0.13911958038806915, 0.026192687451839447, -0.12980109453201294, 0.006291490979492664, 0.011472892947494984, -0.17488133907318115, -0.0970219075679779, 0.07249347865581512, 0.13815297186374664, -0.0008183624595403671, -0.0022903415374457836, 0.0267877746373415, -0.08218586444854736, -0.06938650459051132, 0.036693673580884933, 0.05622674152255058, 0.0011200759327039123, -0.006159467622637749, 0.09437373280525208, -0.03244677931070328, 0.10979581624269485, -0.046667132526636124, 0.05002065375447273, 0.06865119934082031, 0.025013696402311325, 0.0771450623869896, 0.0021125497296452522, -0.07460954040288925, -0.007806217297911644, -0.05995635688304901, 0.020606771111488342, -0.06873470544815063, -0.07270778715610504, -0.07278117537498474, 0.16456708312034607, -0.14248719811439514, 0.14231258630752563, -0.13199083507061005, 0.026849593967199326, -0.0798758864402771, -0.02659347839653492, 0.06637756526470184, -0.188909113407135, -0.0512755885720253, -0.06767657399177551, -0.011834071949124336, 0.09457937628030777, -0.2135598361492157, 0.10224809497594833, 0.12264436483383179], "changes": {"1wk": -0.30457548714359933}}, {"text": "Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer\u2019s Disease Anavex Life Sciences Corp. Wed, Jan 15, 2025, 3:30 PM 7 min read In This Article: AVXL -6.80% Anavex Life Sciences Corp. Blarcamesine potential novel oral treatment to target upstream Alzheimer\u2019s disease pathology through autophagy enhancement Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer\u2019s disease NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that The Journal of Prevention of Alzheimer\u2019s Disease (JPAD) has published peer-reviewed detailed results from the Phase IIb/III study evaluating oral blarcamesine (ANAVEX\u00ae2-73) for the treatment of early Alzheimer\u2019s Disease (AD). Once daily oral blarcamesine, demonstrating a safety profile with no associated neuroimaging adverse events, significantly slowed clinical progression by 36.3% at 48 weeks with blarcamesine group as well as the prespecified SIGMAR1 wild-type gene group by 49.8% at 48 weeks on the prespecified primary cognitive endpoint ADAS-Cog13. Oral once daily blarcamesine could represent a novel treatment in early Alzheimer\u2019s disease and be complementary or alternative to injectable anti-beta amyloid drugs. \u201cThe Alzheimer\u2019s disease community has been actively pursuing new medicines for decades. To have data like these published in JPAD gives us energy and hope. We are now seeing in the data what we suspected about blarcamesine for a long time \u2013 that it has the potential to make a clinical difference for people living with early Alzheimer\u2019s disease,\u201d said senior author behavioral neurologist Professor Dr. Marwan Noel Sabbagh MD, Chairman of the Scientific Advisory Board. \u201cThe advantage of blarcamesine lies in its small oral formulation, which offers clinical benefits for cognition and neurodegeneration. Its ease of administration and favorable safety profile make it an appealing option.\u201d Data from the Phase IIb/III trial demonstrated oral once daily blarcamesine pre-specified clinical efficacy through upstream SIGMAR1 activation. SIGMAR1 is an integral membrane protein which activates an upstream compensatory process: Blarcamesine induces autophagy through SIGMAR1 activation resulting in restoring cellular homeostasis. \u201cThe results from the Phase IIb/III blarcamesine study show real promise for patients living with early Alzheimer\u2019s disease,\u201d said lead author Associate Professor Dr. Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. \u201cEarly Alzheimer\u2019s disease can progress swiftly, and the potential for blarcamesine to target on a constitutional level of the pathology should bring hope and excitement to persons living with Alzheimer\u2019s disease and those of us who care for them.\u201d Story Continues Impaired autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer\u2019s disease. 1 Hence, stabilization or restoration of autophagy can be seen as an early preventative measure countering the Alzheimer\u2019s disease pathology. \u201cPublication of the pivotal placebo-controlled Phase IIb/III blarcamesine early Alzheimer\u2019s disease trial allows for a broader dissemination of these important data and highlights blarcamesine\u2019s impressive and consistent clinical profile that has led to meaningful results for these patients,\u201d said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. \u201cThese data serve as the foundation for the MAA filing that is currently being reviewed by the EMA. We are aiming to potentially advance an important medicine to patients in need.\u201d Blarcamesine, a small molecule administered orally once daily, demonstrated clinically meaningful improvement over 48 weeks with primary endpoint ADAS-Cog13 score being larger than 2 points. 2 This suggests superior numerical clinical efficacy compared to approved therapies while also slowing neurodegeneration in early Alzheimer\u2019s disease patients. Blarcamesine\u2019s safety profile indicates not requiring routine MRI monitoring, and given its differentiated mechanism of action, oral blarcamesine could represent a novel treatment that could be complementary or an alternative to injectable anti-beta amyloid monoclonal antibody drugs. \u201cThe peer-reviewed publication of these data underscores the significance of the findings for both the scientific community and those focused on Alzheimer's disease,\u201d said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. \u201cAlzheimer's disease is a highly complex condition, and this dataset plays a crucial role in advancing our understanding of the Phase IIb/III results. We are grateful to the dedication from participants, their families, and the sites for taking part in this important study.\u201d This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. The publication may be accessed here . About Alzheimer\u2019s Disease There are an estimated 7 million people in Europe with Alzheimer\u2019s disease, a number expected to double by 2030, according to the European Brain Council. 3 The World Health Organization (WHO) estimated the cost in Europe of caring for people with dementia, including Alzheimer's disease, at $439 billion, or $31,144 per person in 2019. That includes hospital care, medicines, diagnostics, informal caregiver time, community services and long-term care facility costs. 4 , 5 About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX\u00ae2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX\u00ae2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX\u00ae2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX\u00ae2-73 for the treatment of Parkinson's disease. We believe that ANAVEX\u00ae3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX\u00ae3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn . Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com __________________________ 1 Christ MG, Clement AM, Behl C. The Sigma-1 Receptor at the Crossroad of Proteostasis, Neurodegeneration, and Autophagy. Trends Neurosci. 2020 Feb;43(2):79-81; Chen, J., He, HJ., Ye, Q. et al. Defective Autophagy and Mitophagy in Alzheimer\u2019s Disease: Mechanisms and Translational Implications. Mol Neurobiol 58, 5289\u20135302 (2021). 2 Muir RT, Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer's disease: Rapid review.\u00a0Alzheimers Dement. 2024;20(5):3352-3363. doi:10.1002/alz.13770 3 https://www.braincouncil.eu/projects/rethinking-alzheimers-disease/ 4 J\u00f6nsson L. The personal economic burden of dementia in Europe. Lancet Reg Health Eur. 2022 Jul 25;20:100472. doi: 10.1016/j.lanepe.2022.100472. PMID: 35910037; PMCID: PMC9326307. 5 World Health Organization (WHO); 2021. Global status report on the public health response to dementia. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-15T12:30:00+00:00", "sentiment": {"score": 0.815584909170866, "confidence": 0.829078733921051, "probabilities": {"positive": 0.829078733921051, "negative": 0.013493824750185013, "neutral": 0.15742747485637665}}, "embedding": [-0.15228308737277985, -0.20934753119945526, -0.03574618697166443, -0.03975476324558258, -0.04893862456083298, 0.0326305516064167, -0.04475441575050354, 0.2665550708770752, 0.06988030672073364, 0.09749683737754822, -0.14892695844173431, 0.12308423221111298, 0.0015845608431845903, 0.17613685131072998, -0.027301933616399765, 0.26091697812080383, -0.10671789944171906, -0.015158958733081818, -0.06188986822962761, 0.1744948923587799, 0.027553701773285866, -0.07458843290805817, 0.12576183676719666, 0.10606469213962555, -0.01092888880521059, 0.03579264134168625, -0.06799864768981934, -0.14670583605766296, -0.10378096997737885, 0.043449871242046356, 0.09003591537475586, 0.09627170860767365, 0.07890325784683228, -0.03269951045513153, 0.008174394257366657, -0.11970333009958267, -0.14434856176376343, 0.05168392136693001, -0.26766887307167053, -0.06980730593204498, -0.11411627382040024, 0.09136223793029785, -0.05479027330875397, -0.021050117909908295, -0.033931367099285126, -0.1740342080593109, 0.03906594216823578, -0.006371989380568266, 0.06540532410144806, 0.03341345489025116, -0.12295021116733551, -0.10927575826644897, 0.015766510739922523, 0.0843622013926506, -0.06022021174430847, 0.232338547706604, -0.15478743612766266, -0.045089319348335266, 0.030036982148885727, 0.09051206707954407, -0.06751543283462524, -0.11298626661300659, 0.04095037281513214, -0.061202459037303925, -0.029058078303933144, 0.12290392816066742, 0.024699624627828598, -0.03017580136656761, 0.010386406444013119, 0.0021744612604379654, -0.02631651610136032, -0.10334186255931854, -0.10386036336421967, 0.16723638772964478, 0.11695008724927902, 0.014801801182329655, 0.07841689884662628, 0.03357619792222977, -0.005023202858865261, -0.3512127995491028, 0.047053493559360504, 0.05179758742451668, 0.10681740939617157, 0.1705477386713028, 0.16921943426132202, -0.00333264097571373, 0.09158818423748016, 0.1773700714111328, 0.08712390065193176, 0.00239398330450058, 0.06629355251789093, 0.021889204159379005, -0.13136403262615204, -0.051412731409072876, 0.10793756693601608, -0.11465895175933838, 0.011390212923288345, 0.0860179215669632, 0.08258061856031418, -0.023209478706121445, -0.019472576677799225, 0.05918451398611069, -0.15500876307487488, -0.032404061406850815, 0.03863387554883957, 0.016780568286776543, 0.10074136406183243, -0.030287545174360275, 0.14160171151161194, -0.04926531761884689, 0.04374082386493683, 0.1164424791932106, 0.11780554056167603, 0.014344881288707256, -0.05608729273080826, 0.043390095233917236, 0.005571971647441387, -0.01124109048396349, 0.1204201802611351, 0.0319502130150795, 0.2047639936208725, -0.009072907269001007, 0.1150837168097496, -0.14072269201278687, 0.014237599447369576, 0.11088508367538452, -0.05616379156708717, 1.3262160895479274e-32, -0.14841711521148682, -0.027615860104560852, -0.0009849648922681808, 0.09134837985038757, -0.09212912619113922, -0.006514777895063162, -0.0947333425283432, -0.013903885148465633, -0.005484326742589474, -0.18763339519500732, -0.08301731944084167, -0.12633116543293, -0.016694506630301476, 0.19061455130577087, -0.021654749289155006, 0.0662950724363327, -0.08009074628353119, -0.05832739174365997, -0.001752032432705164, -0.0007660486735403538, -0.04801320284605026, 0.005596732255071402, -0.1100451722741127, 0.030793244019150734, -0.06526456028223038, -0.06239093840122223, 0.04862603917717934, 0.1730540692806244, 0.11355900764465332, 0.0013891374692320824, -0.04058250039815903, -0.00761505588889122, -0.11409451812505722, -0.13799601793289185, -0.15040022134780884, 0.09022548794746399, 0.02724120393395424, -0.08258691430091858, -0.13424012064933777, 0.0441451370716095, 0.08267912268638611, 0.0962887704372406, -0.23809073865413666, 0.003796424251049757, 0.027925854548811913, -0.07462350279092789, -0.040335655212402344, 0.035982802510261536, -0.029438404366374016, -0.007662038318812847, 0.09367240965366364, -0.04391368851065636, -0.06700862944126129, 0.0015007734764367342, -0.14731915295124054, 0.0695476159453392, -0.05551358684897423, -0.05832688882946968, 0.15142673254013062, 0.0843479186296463, 0.08433489501476288, 0.05894674360752106, -0.01324302889406681, 0.023506248369812965, 0.015090801753103733, 0.08257188647985458, 0.09843267500400543, -0.027323070913553238, -0.17269402742385864, -0.06593542546033859, 0.07828094810247421, -0.038136351853609085, 0.15778417885303497, -0.04057846590876579, 0.02325454354286194, -0.050892364233732224, 0.09165211021900177, 0.05086562782526016, -0.05926132947206497, -0.1025092750787735, -0.04032883793115616, -0.02434157207608223, -0.015211887657642365, 0.08887876570224762, -0.04513951390981674, -0.05891717970371246, 0.08636367321014404, -0.06488553434610367, -0.20153021812438965, -0.005979451816529036, 0.1409948170185089, -0.05738510936498642, 0.025819266214966774, 0.15922105312347412, -0.15099473297595978, -1.2275768320873767e-32, -0.2072744071483612, 0.025462234392762184, -0.07208776473999023, -0.1134900152683258, -0.10589946061372757, 0.168158620595932, 0.20638003945350647, -0.054101429879665375, 0.22157186269760132, -0.3410782217979431, 0.10358208417892456, 0.05659112334251404, 7.434748113155365e-05, 0.01230873167514801, 0.03829089552164078, -0.02471575327217579, -0.061040379106998444, -0.04480791091918945, -0.07561878859996796, 0.04906521365046501, -0.01106085255742073, 0.2439398318529129, -0.04395299404859543, 0.12641176581382751, 0.07176275551319122, 0.09407935291528702, 0.03280814737081528, 0.1383610963821411, 0.05261707678437233, -0.04110131040215492, 0.09799957275390625, 0.10802990943193436, -0.10515221953392029, -0.09342780709266663, -0.03173192963004112, 0.04191364720463753, 0.08218905329704285, -0.30484437942504883, -0.1625579297542572, -0.18528211116790771, -0.00490350928157568, 0.0877297967672348, -0.06247501075267792, -0.13590608537197113, 0.04918131232261658, 0.06060805916786194, 0.03621123731136322, -0.04187271371483803, -0.023153431713581085, 0.008723647333681583, -0.009033509530127048, -0.0581926628947258, -0.0215629730373621, -0.07135427743196487, 0.015615371987223625, -0.14295391738414764, -0.056855976581573486, -0.13616079092025757, 0.03520696610212326, -0.015072842128574848, -0.0343545526266098, 0.13836538791656494, -0.015340004116296768, -0.010653635486960411, 0.0936364084482193, 0.13149724900722504, 0.1165696382522583, 0.12529996037483215, -0.02726217359304428, -0.0895576998591423, -0.0114500243216753, 0.04483645036816597, 0.01946605183184147, 0.07527732849121094, 0.042788080871105194, 0.13056623935699463, -0.015641767531633377, -0.11940710246562958, -0.10810910165309906, -0.12508726119995117, -0.1992337703704834, -0.02878606505692005, -0.040770161896944046, 0.029294144362211227, -0.04395027458667755, -0.08149437606334686, -0.11096064746379852, -0.059624455869197845, 0.09895678609609604, 0.021084101870656013, -0.07085450738668442, -0.1765182912349701, -0.05530516058206558, 0.11179948598146439, -0.06683593988418579, -1.0028158214936411e-07, 0.1789425015449524, -0.12168003618717194, 0.04100637510418892, 0.03159220889210701, 0.11580894887447357, -0.20149782299995422, -0.02565355971455574, 0.1245427280664444, -0.06840876489877701, 0.0711088702082634, 0.07219049334526062, 0.14792205393314362, -0.0624452605843544, 0.014371254481375217, -0.13970090448856354, 0.0639612004160881, 0.029944779351353645, -0.027915146201848984, -0.08590850979089737, -0.09733788669109344, -0.09927691519260406, 0.05642058700323105, 0.0090558510273695, -0.1576848179101944, 0.09195418655872345, -0.1980009227991104, 0.09979353845119476, 0.12866126000881195, 0.054817184805870056, -0.22646859288215637, -0.07424713671207428, 0.09939422458410263, 0.0345085971057415, 0.13080045580863953, 0.05586342513561249, -0.13824474811553955, 0.05742323398590088, 0.22995802760124207, 0.07415797561407089, 0.1392429769039154, 0.043754369020462036, -0.14911837875843048, 0.017429523169994354, -0.01419799029827118, -0.020826851949095726, 0.015476113185286522, -0.06211778521537781, -0.02817765437066555, 0.11500894278287888, -0.08516250550746918, 0.04925701767206192, 0.10389968752861023, 0.10230205208063126, 0.06092209741473198, -0.1355028599500656, 0.08116459846496582, -0.09581742435693741, -0.018326763063669205, 0.1476474404335022, -0.23778441548347473, 0.0007461821660399437, 0.018076006323099136, 0.1417093724012375, 0.14324283599853516], "changes": {"1wk": -13.062661537531756}}, {"text": "New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer\u2019s Disease Patients Anavex Life Sciences Corp. Mon, Jan 13, 2025, 3:30 PM 9 min read In This Article: AVXL -6.80% Anavex Life Sciences Corp. Topline ATTENTION-AD trial: Patients showed improved cognition and function over three years Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation Blarcamesine exhibited a favorable safety profile with no treatment-related deaths NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX \u00ae 2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer\u2019s disease patients. No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good comparative safety profile and no associated neuroimaging adverse events. There were no deaths related to the study drug. The ATTENTION-AD (ANAVEX \u00ae 2-73-AD-EP-004) trial followed the 48-week ANAVEX \u00ae 2-73-AD-004 double-blind (DB) clinical trial with an open-label extension (OLE) treatment duration of 96 weeks for participants in North America and Europe and up to 144 weeks for participants in Australia 1 to evaluate the safety and tolerability of blarcamesine and long-term effects of blarcamesine on cognition and function in participants with early Alzheimer\u2019s disease. 2 Blarcamesine-treated patients continue to accrue benefit through up to 4 years, as measured by the clinical endpoints ADAS-Cog13 and ADCS-ADL. Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation. \u201cLong-term clinical ATTENTION-AD study results support the importance of continued long-term blarcamesine treatment,\u201d said Prof. Dr. Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX \u00ae 2-73-AD-004 study. \u201cBlarcamesine is easily scalable and might be a potential therapeutic solution for Alzheimer\u2019s disease patients to potentially offer hope and relief and equitable and accessible for diverse populations and maintaining sustainability within the global healthcare systems.\u201d Topline Efficacy Data: The delayed-start analysis was performed using the prespecified Mixed effect Model Repeat Measure (MMRM) model, to evaluate the effect of early treatment with blarcamesine on all data collected in both DB and OLE phases as the potential indication of disease-modifying characteristics of the treatment. Comparisons were made between \u2018Continued blarcamesine\u2019 and \u2018Placebo to blarcamesine\u2019 for ADAS-Cog13 and ADCS-ADL at the scheduled visits. \u2018Continued blarcamesine\u2019 is the early start group and \u2018Placebo to blarcamesine\u2019 is the late start group. Story Continues The delayed-start analysis for ADAS-Cog13 showed a significant difference between early start and late start treatment groups at Week 144 (LS mean difference -2.70, P = 0.0348), favoring the early start group. This observed treatment difference continued to increase up to Week 192 (LS mean difference -3.83, P = 0.0165). Together these results suggest that participants who initiated treatment with blarcamesine earlier in their disease progression showed greater stability of cognitive function compared to those who did not initiate blarcamesine until ~1 year later. In addition, to place these findings in context, an ADAS-Cog13 score LS mean difference between the treatment groups at both Week 144 (OLE Week 96) and Week 192 (OLE Week 144) being larger than 2 points are considered clinically meaningful improvements. 3 Similarly, the delayed-start analysis for ADCS-ADL showed numerically favorable results for the early start group over the late start group at Week 144 (LS mean difference +2.32, P = 0.125). The treatment difference continued to increase up to Week 192 and reached statistical significance (LS mean difference +4.30, P = 0.0206). This suggests that earlier initiation of treatment with blarcamesine may have a significant positive impact on disease progression and may provide continued benefits to patients with early Alzheimer\u2019s disease over the long-term. Topline Safety Data: Blarcamesine exhibited a favorable safety profile with the majority of adverse events (AEs) mild to moderate in severity (Grade 1 or 2), were predominantly linked to the initial titration phase, and could be managed with adjusted titration schedules. Importantly, no severe or life-threatening adverse events were attributed to blarcamesine. There were no deaths related to blarcamesine. The ATTENTION-AD trial demonstrated the manageable nature of the most frequent treatment emergent adverse event (TEAE) of dizziness observed in the preceding ANAVEX \u00ae 2-73-AD-004 trial, which was generally transient in duration (approx. 7-11 days) and mild or moderate in severity (Grade 1 or 2). The titration schedule was adjusted to a slightly longer titration period in the ATTENTION-AD trial, from previous 2-3 weeks to 10 weeks. A markedly lower frequency of the TEAE of dizziness in the respective maintenance phase was observed: from previously 25.2% in the ANAVEX \u00ae 2-73-AD-004 trial to 9.6% in the ATTENTION-AD trial, demonstrating the manageable nature of the most frequent TEAE (dizziness). Furthermore, no notable findings were observed over time in vital sign, clinical laboratory test, physical examination, electrocardiogram (ECG), and no pattern of serious adverse events (SAEs) were reported. Compassionate Use: Lastly, there are currently 74 participants receiving blarcamesine within the Compassionate Use Program, who continued treatment with blarcamesine subsequent completion of respective preceding open-label-extension studies from both ANAVEX \u00ae 2-73-AD-EP-004 in early AD and from ANAVEX \u00ae 2-73-003 in mild-to-moderate AD. Including the start of the respective preceding studies, some participants are on oral blarcamesine once daily for over 9 years. Importantly, no severe or life-threatening adverse events were attributed to blarcamesine. \u201cThese results demonstrate that diagnosing and treating people earlier in the progression of Alzheimer's disease may lead to greater clinical benefit,\u201d said Juan Carlos Lopez-Talavera, MD, PhD, Head of Research and Development of Anavex. \u201cAdditionally, the comprehensive data from the blarcamesine Alzheimer\u2019s disease program represents a solid foundation for the subsequent strategy of our Phase III and IV development plan.\u201d \u201cAlzheimer\u2019s disease, like other chronic progressive diseases, requires a long-term therapeutic strategy. Blarcamesine mechanism of action with its convenient once daily oral dosing supports long-term therapy,\u201d said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. \u201cWe remain excited about the scalable and convenient features of oral blarcamesine, which could be appealing because of its route of administration and good comparative safety profile. This could reduce crucial barriers within the currently complex healthcare ecosystem for Alzheimer's disease and potentially provide broader access to a diverse population with early Alzheimer's disease.\u201d ATTENTION-AD (ANAVEX \u00ae 2-73-AD-EP-004) trial result details will be presented at the upcoming AD/PD\u2122\u00a02025 Conference. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX \u00ae 2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX \u00ae 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX \u00ae 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX \u00ae 2-73 for the treatment of Parkinson's disease. We believe that ANAVEX \u00ae 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX \u00ae 3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn . Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com ____________________ 1 The preceding double-blind trial (ANAVEX \u00ae 2-73-AD-004) began in Australia before the other regions (Europe and North America), leaving insufficient time for the other regions to participate in the additional OLE extension beyond the initial 96 Weeks OLE period. The extension, requested by investigators in Australia, extended the initial 96-Week OLE period to 144 Weeks. 2 The scheduled visits were [OLE Week 0 = Combined Week 48], [OLE Week 48 = Combined Week 96], [OLE Week 96 = Combined Week 144] and [OLE Week 144 = Combined Week 192]; Combined = OLE (open-label-extension) + DB (double-blind) trials. 3 Muir RT, Hill MD, Black SE, Smith EE. Minimal clinically important difference in Alzheimer's disease: Rapid review.\u00a0Alzheimers Dement. 2024;20(5):3352-3363. doi:10.1002/alz.13770 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-13T12:30:00+00:00", "sentiment": {"score": 0.6049369350075722, "confidence": 0.6227379441261292, "probabilities": {"positive": 0.6227379441261292, "negative": 0.017801009118556976, "neutral": 0.3594610393047333}}, "embedding": [-0.044846758246421814, -0.1900690793991089, -0.03256523609161377, -0.09021399915218353, -0.058000482618808746, 0.08439356088638306, -0.06436377763748169, 0.276634156703949, 0.11544259637594223, 0.1413230299949646, -0.08557011187076569, 0.10428281128406525, -0.022891469299793243, 0.167848140001297, 0.021520130336284637, 0.23968663811683655, -0.011776815168559551, 0.030142948031425476, -0.09887496381998062, 0.14307661354541779, 0.0906970277428627, -0.05700971931219101, 0.09692535549402237, 0.12352889776229858, -0.10325434803962708, 0.08272765576839447, -0.10680777579545975, -0.10601472109556198, -0.09269236773252487, 0.0829043835401535, 0.11698485910892487, -0.00663144001737237, 0.09439076483249664, -0.03290624916553497, -0.022052405402064323, -0.09399573504924774, -0.20381298661231995, 0.046789880841970444, -0.283833771944046, -0.014433157630264759, -0.19875308871269226, 0.09331276267766953, -0.12707354128360748, 0.012057561427354813, 0.01818177103996277, -0.16089390218257904, 0.08946748077869415, -0.010049889795482159, 0.04845816269516945, -0.014284597709774971, -0.07656537741422653, -0.10476359724998474, 0.06041388213634491, 0.02823173999786377, -0.05159589648246765, 0.1514883041381836, -0.12721577286720276, 0.015451512299478054, 0.00585956359282136, 0.09025301039218903, -0.14040303230285645, -0.09958382695913315, 0.051186077296733856, -0.0910545215010643, -0.03494514897465706, 0.16029015183448792, 0.01261622179299593, -0.18287858366966248, -0.03489925339818001, -0.00601777620613575, -0.02404886856675148, -0.143483966588974, -0.06326299905776978, 0.07820542901754379, 0.08111649006605148, -0.005893923342227936, 0.09406697750091553, 0.06679745018482208, -0.053139425814151764, -0.3591376543045044, 0.07927697151899338, 9.248033165931702e-07, 0.002929487731307745, 0.10255715250968933, 0.18778765201568604, -0.00367802195250988, 0.12513846158981323, 0.18249841034412384, 0.06881222128868103, 0.0002237493172287941, 0.08552293479442596, 0.03385503217577934, -0.1275726556777954, -0.051381081342697144, 0.1235874742269516, -0.1903081238269806, -0.017260577529668808, 0.12749996781349182, 0.0626642107963562, -0.028107525780797005, 0.031530238687992096, 0.02280685305595398, -0.22623342275619507, -0.03771428018808365, 0.05266747251152992, 0.016300231218338013, 0.10704034566879272, -0.053966015577316284, 0.1495077908039093, -0.044719550758600235, 0.02688560076057911, 0.07802130281925201, 0.10613188147544861, 0.042484961450099945, -0.09130273759365082, 0.033846236765384674, -0.07473880797624588, -0.004470598418265581, 0.23364773392677307, 0.019152747467160225, 0.320345401763916, -0.03796738386154175, 0.13488368690013885, -0.1086195856332779, 0.050428956747055054, 0.10068643093109131, 0.017539404332637787, 1.2855054875694868e-32, -0.16201569139957428, -0.06929261982440948, -0.0612993948161602, 0.0788191556930542, -0.0635489970445633, -0.01832817867398262, -0.005766892805695534, 0.019097456708550453, -0.03376173600554466, -0.14742404222488403, -0.047666583210229874, -0.12933430075645447, 0.002240354660898447, 0.21182981133460999, 0.0020697959698736668, 0.09824250638484955, -0.03175005316734314, -0.010628167539834976, -0.03397098556160927, -0.022107955068349838, -0.0541117899119854, -0.057269927114248276, -0.056058913469314575, 0.14807426929473877, -0.1095113530755043, -0.07729963958263397, 0.039214715361595154, 0.174280047416687, 0.05988436937332153, -0.051345095038414, 0.002347777597606182, -0.007156768813729286, -0.051223039627075195, -0.160319983959198, -0.2025480568408966, 0.06642335653305054, 0.06202054023742676, -0.07158738374710083, -0.0878172442317009, 0.010500989854335785, 0.13962191343307495, 0.14943240582942963, -0.16099783778190613, 0.02593172714114189, 0.0630318820476532, -0.14333944022655487, -0.10499031096696854, 0.07387056946754456, -0.018679626286029816, 0.008505894802510738, 0.07545102387666702, -0.10005126893520355, -0.07947808504104614, -0.04051956534385681, -0.1322992742061615, 0.15366625785827637, -0.06186177581548691, 0.006359925493597984, 0.12989705801010132, 0.005749476607888937, 0.05618537217378616, 0.03319435194134712, 0.01650240458548069, 0.033403996378183365, -0.032104138284921646, 0.12956726551055908, 0.13323146104812622, -0.01735938899219036, -0.16204401850700378, -0.06783822178840637, 0.041022658348083496, -0.021786846220493317, 0.13052450120449066, -0.003964577801525593, 0.029175611212849617, -0.025848185643553734, 0.08439452946186066, 0.006155773997306824, -0.018148768693208694, -0.13615714013576508, 0.039302434772253036, -0.04875180870294571, -0.026740361005067825, 0.1522027999162674, -0.07422639429569244, -0.073905810713768, 0.03697776794433594, -0.042699359357357025, -0.25781533122062683, 0.038513243198394775, 0.08574105054140091, -0.040142834186553955, 0.013735787943005562, 0.09435330331325531, -0.07927718758583069, -1.2269281061425167e-32, -0.1856168955564499, 0.11231933534145355, -0.10861337184906006, -0.14088958501815796, -0.0933561623096466, 0.1129724383354187, 0.14567670226097107, -0.05036833882331848, 0.19806215167045593, -0.3124316334724426, 0.08779289573431015, 0.031316813081502914, 0.05047506093978882, 0.003555707633495331, -0.034273259341716766, 0.020444342866539955, -0.02327786758542061, -0.01535072922706604, -0.1295997053384781, 0.06423382461071014, 0.030138429254293442, 0.16538000106811523, -0.02745460718870163, 0.04893162101507187, 0.07100820541381836, 0.07622236013412476, 0.014312888495624065, 0.06549027562141418, 0.08647765219211578, -0.09933504462242126, 0.04437091946601868, 0.08348985016345978, -0.13735026121139526, -0.016057906672358513, -0.06680655479431152, 0.030695144087076187, 0.08329877257347107, -0.2978783845901489, -0.21664711833000183, -0.04719245061278343, -0.03345608338713646, 0.0931871235370636, -0.0161967221647501, -0.13847362995147705, 0.026657605543732643, 0.038968756794929504, 0.07686727494001389, -0.08902005851268768, -0.10076751559972763, 0.01932618021965027, -0.06990371644496918, -0.05426853895187378, 0.005947277881205082, -0.09022586047649384, -0.013006646186113358, -0.17555248737335205, -0.07931523025035858, -0.13886642456054688, -0.025328440591692924, -0.10052275657653809, 0.05440916121006012, 0.17169798910617828, 0.00043556466698646545, -0.00016591977328062057, 0.07067205756902695, 0.19232356548309326, 0.09219144284725189, 0.14205384254455566, 0.09328170120716095, -0.17527970671653748, 0.03620704263448715, 0.07910201698541641, -0.015107963234186172, 0.05733324587345123, -0.012390905991196632, 0.13388721644878387, -0.057360053062438965, -0.07952132821083069, -0.11677400767803192, -0.1339835375547409, -0.15311169624328613, -0.08046780526638031, -0.05338418856263161, 0.06922289729118347, -0.084542416036129, -0.028570041060447693, -0.03753030300140381, -0.06831066310405731, 0.1273001879453659, -0.038202714174985886, -0.07012692093849182, -0.13988299667835236, 0.012739541009068489, 0.12197334319353104, -0.08694577217102051, -1.0086043289447844e-07, 0.05855507403612137, -0.08308997005224228, 0.013608125038444996, 0.0405096560716629, 0.10640953481197357, -0.16743803024291992, -0.0340023897588253, 0.1022769957780838, -0.13515529036521912, 0.013309897854924202, 0.048540398478507996, 0.10524016618728638, -0.07758542150259018, 0.010482856072485447, -0.13114818930625916, 0.07602154463529587, 0.06225278973579407, -0.06310749053955078, 0.004815062507987022, -0.012067092582583427, -0.21700233221054077, 0.04917767643928528, 0.009431261569261551, -0.18315941095352173, 0.05943771079182625, -0.16609984636306763, 0.09943723678588867, 0.151152104139328, 0.07254403829574585, -0.20480352640151978, -0.006778026930987835, 0.06367941945791245, 0.09689337015151978, 0.05302456393837929, 0.03782832249999046, -0.1727868616580963, 0.008120852522552013, 0.2957780361175537, 0.11473813652992249, 0.16607090830802917, 0.04538596421480179, -0.07900525629520416, 0.04660501331090927, 0.0696318969130516, 0.005764476954936981, -0.00039506610482931137, -0.11633455753326416, -0.047764651477336884, 0.10873506963253021, -0.0951959490776062, 0.10456066578626633, 0.1475319266319275, 0.0776326134800911, 0.04955790191888809, -0.15134736895561218, 0.057698577642440796, -0.04357810318470001, -0.034014150500297546, 0.10786767303943634, -0.24028190970420837, 0.028701504692435265, 0.06783135235309601, 0.08341462910175323, 0.11699578166007996], "changes": {"1wk": -12.701423017647857}}, {"text": "Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL) Zacks Equity Research Tue, Jan 7, 2025, 4:50 PM 3 min read Most of us have heard the dictum \"the trend is your friend.\" And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Investors looking to make a profit from stocks that are currently on the move may find our \"Recent Price Strength\" screen pretty useful. This predefined screen comes handy in spotting stocks that are on an uptrend backed by strength in their fundamentals, and trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullishness. There are several stocks that passed through the screen and Anavex Life Sciences (AVXL) is one of them. Here are the key reasons why this stock is a solid choice for \"trend\" investing. A solid price increase over a period of 12 weeks reflects investors' continued willingness to pay more for the potential upside in a stock. AVXL is quite a good fit in this regard, gaining 142.3% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that might have happened in a shorter time frame. It's important for a potential winner to maintain the price trend. A price increase of 58% over the past four weeks ensures that the trend is still in place for the stock of this biopharmaceutical company. Moreover, AVXL is currently trading at 88.1% of its 52-week High-Low Range, hinting that it can be on the verge of a breakout. Looking at the fundamentals, the stock currently carries a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises -- the key factors that impact a stock's near-term price movements. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Another factor that confirms the company's fundamental strength is its Average Broker Recommendation of #1 (Strong Buy). This indicates that the brokerage community is highly optimistic about the stock's near-term price performance. Story Continues So, the price trend in AVXL may not reverse anytime soon. In addition to AVXL, there are several other stocks that currently pass through our \"Recent Price Strength\" screen. You may consider investing in them and start looking for the newest stocks that fit these criteria. This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market. However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies. Click here to sign up for a free trial to the Research Wizard today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-07T13:50:10+00:00", "sentiment": {"score": 0.3601137064397335, "confidence": 0.38516491651535034, "probabilities": {"positive": 0.38516491651535034, "negative": 0.025051210075616837, "neutral": 0.5897838473320007}}, "embedding": [-0.07658985257148743, -0.016066420823335648, -0.0005079158581793308, 0.044527288526296616, 0.06868502497673035, 0.0663892924785614, 0.005387851968407631, 0.08080706745386124, 0.1764378398656845, 0.14116907119750977, -0.15219223499298096, 0.1259140968322754, -0.04163060337305069, -0.04997321218252182, -0.05659159645438194, -0.08476877212524414, -0.14206600189208984, -0.050980664789676666, -0.09363318979740143, 0.09758453071117401, -0.08002245426177979, -0.1978418529033661, 0.07061178982257843, 0.002239345572888851, 0.01603042334318161, 0.07259511947631836, 0.025919754058122635, 0.06584025174379349, -0.11240445077419281, -0.07869627326726913, -0.005572957918047905, 0.14557960629463196, 0.10899542272090912, -0.055206045508384705, -0.1788257658481598, -0.007120562717318535, -0.05984512344002724, 0.04150354117155075, 0.0398937463760376, -0.0014507747255265713, -0.043468229472637177, 0.03226320445537567, -0.12839651107788086, 0.08419311046600342, -0.08978629857301712, -0.20305640995502472, 0.0022989725694060326, -0.0780724287033081, 0.10483509302139282, -0.007596490904688835, -0.22755123674869537, -0.10084208846092224, -0.02260267734527588, 0.004273625090718269, -0.13214729726314545, 0.12184617668390274, -0.07248146086931229, -0.060788534581661224, 0.07239411026239395, -0.05593026801943779, 0.10030445456504822, 0.02722027525305748, 0.00967365875840187, -0.06499860435724258, 0.02467402070760727, -0.0721120685338974, 0.03605424612760544, 0.06168827787041664, 0.012983647175133228, 0.18290698528289795, 0.06119895726442337, -0.06367649883031845, -0.08104314655065536, -0.01762140914797783, 0.09279685467481613, 0.07079993188381195, 0.09007133543491364, -0.0924566462635994, 0.11425258219242096, -0.06520445644855499, -0.001627977006137371, -0.009414711967110634, -0.03514407202601433, -0.0014650747179985046, 0.04229366034269333, -0.030066736042499542, 0.14637726545333862, -0.024266764521598816, 0.07188348472118378, 0.024153951555490494, 0.03813071548938751, -0.010552480816841125, -0.06459710001945496, -0.07798559218645096, 0.22429464757442474, 0.09896373748779297, -0.09533554315567017, -0.07551068067550659, -0.017827413976192474, 0.059726253151893616, 0.15833967924118042, 0.05692684277892113, -0.053719982504844666, -0.029980288818478584, 0.0441964715719223, -0.12641669809818268, -0.008927764371037483, -0.06650044769048691, 0.06197206676006317, 0.011556040495634079, -0.1267833113670349, 0.14818303287029266, -0.01973208785057068, -0.027055710554122925, -0.043424200266599655, 0.1094609946012497, -0.05142569541931152, -0.06994856894016266, -0.010065022855997086, 0.0570334792137146, 0.057955652475357056, -0.004477277398109436, -0.03088555485010147, 0.02822010964155197, 0.07382743805646896, 0.10140880942344666, -0.11006295680999756, 5.201701357658813e-33, -0.015979111194610596, 0.02292422577738762, -0.05762084573507309, 0.0695599764585495, -0.1172458678483963, -0.017712228000164032, 0.04018135368824005, -0.08174566924571991, -0.08408516645431519, -0.051916372030973434, -0.1213260218501091, 0.1754423975944519, -0.046228595077991486, 0.037458889186382294, 0.05460657924413681, -0.1606648564338684, -0.051993392407894135, -0.02160845324397087, 0.022219199687242508, -0.0349452905356884, -0.0510723777115345, -0.10098305344581604, -0.055269647389650345, -0.042830802500247955, -0.0436461865901947, -0.079747773706913, -0.010752885602414608, 0.022797608748078346, -0.09105540066957474, 0.025967005640268326, 0.07597840577363968, 0.08606737852096558, -0.09757980704307556, -0.13804835081100464, -0.04530663043260574, -0.06137724965810776, -0.08336016535758972, -0.014121320098638535, 0.14574530720710754, 0.024539727717638016, -0.12722903490066528, 0.14750666916370392, -0.06378238648176193, -0.05191480740904808, 0.0451076477766037, 0.13769912719726562, 0.008466312661767006, 0.031596891582012177, -0.09682652354240417, 0.00944945402443409, 0.05541061609983444, -0.030118428170681, 0.05893588066101074, -0.031167415902018547, -0.09526026993989944, 0.13418391346931458, 0.021802861243486404, -0.08749674260616302, -0.016773706302046776, 0.06617884337902069, 0.03298062086105347, 0.11380637437105179, 0.11128950864076614, 0.009816866368055344, -0.17790842056274414, 0.162154883146286, -0.020130759105086327, 0.007947582751512527, -0.1728258728981018, 0.23194169998168945, 0.03793365880846977, 0.15345408022403717, 0.028307724744081497, -0.1560906171798706, 0.13290637731552124, -0.01986842229962349, -0.09164848178625107, 0.0011902404949069023, 0.027592670172452927, -0.009855983778834343, 0.08019425719976425, -0.0642767995595932, 0.1083795428276062, -0.01598040945827961, 0.01840016059577465, -0.08742357790470123, -0.03221731260418892, -0.07946136593818665, -0.09620591998100281, -0.002680349163711071, 0.026286838576197624, -0.06284838169813156, -0.005056960508227348, 0.14487621188163757, -0.03058951161801815, -5.392363969968296e-33, -0.08406554907560349, -0.10088898241519928, -0.08975304663181305, 0.038899973034858704, -0.048131413757801056, 0.051278192549943924, 0.10185962915420532, 0.056437380611896515, -0.04679673910140991, -0.09128871560096741, 0.05276883393526077, 0.116164930164814, -0.03610556945204735, 0.04096854850649834, -0.0061053079552948475, -0.05991632118821144, 0.07762500643730164, -0.1285211741924286, 0.074318066239357, -0.1080390214920044, -0.054450150579214096, 0.15282228589057922, -0.1968967169523239, 0.12254997342824936, 0.07477889955043793, 0.07368014752864838, -0.05677497386932373, 0.2014583945274353, -0.036765206605196, -0.07224098592996597, -0.10221485793590546, 0.06328465044498444, 0.027770720422267914, -0.012114378623664379, -0.020931635051965714, 0.08315514773130417, 0.050627171993255615, -0.17028731107711792, -0.09710638225078583, 0.0731477439403534, 0.10927283763885498, 0.06585948914289474, 0.20445281267166138, -0.09760288149118423, 0.04063934460282326, 0.033827029168605804, 0.07316750288009644, 0.07889176905155182, 0.08933155238628387, 0.11886946856975555, 0.09327246248722076, 0.011173659935593605, -0.008497152477502823, 0.13089635968208313, -0.05278316140174866, 0.12005054205656052, -0.1457863450050354, 0.04594447463750839, -0.1403980404138565, 0.06503038853406906, -0.022086329758167267, 0.17516402900218964, 0.09246748685836792, -0.013200456276535988, 0.009165838360786438, 0.03395075723528862, -0.02137746475636959, -0.05486417934298515, -0.03128219395875931, -0.06039024144411087, 0.04236062616109848, 0.042142122983932495, -0.05381045117974281, -0.01518818736076355, 0.016648784279823303, 0.12529940903186798, -0.017848100513219833, -0.08046147227287292, -0.0038941684179008007, 0.025013834238052368, -0.12017147243022919, 0.010759832337498665, -0.04503241926431656, 0.04773388057947159, -0.18239732086658478, 0.13275036215782166, -0.149739608168602, 0.016349034383893013, -0.018928159028291702, -0.07119279354810715, 0.011253256350755692, -0.19038942456245422, -0.105746790766716, -0.03223920613527298, -0.01827917993068695, -9.95391005176316e-08, -0.019326698035001755, -0.04249182716012001, 0.07252537459135056, -0.009696145541965961, 0.150300070643425, -0.03439328819513321, 0.09314066171646118, -0.00784315075725317, 0.13914646208286285, 0.08402779698371887, 0.15194740891456604, 0.04753708094358444, -0.14504235982894897, 0.07479646801948547, -0.09386712312698364, -0.0009531130781397223, -0.10232673585414886, 0.011022833175957203, -0.04868977516889572, -0.1555609107017517, -0.035488590598106384, 0.07340721786022186, 0.05667928606271744, 0.026692595332860947, 0.1081579327583313, -0.06971411406993866, 0.0712544396519661, 0.06848117709159851, 0.01924167200922966, -0.028210658580064774, -0.04201427474617958, -0.03976621478796005, 0.016415376216173172, 0.07755774259567261, -0.04815156012773514, 0.12615284323692322, 0.092842236161232, 0.0598028227686882, 0.04916694015264511, 0.13634741306304932, 0.05321304127573967, -0.0004356019198894501, 0.015470042824745178, -0.050687164068222046, -0.05846601352095604, 0.0012757312506437302, -0.02361961454153061, -0.014556607231497765, 0.14098945260047913, -0.23767249286174774, 0.0534597709774971, -0.04610319435596466, 0.01025887206196785, 0.0993785411119461, -0.05118653178215027, -0.011732341721653938, -0.1589668095111847, -0.013234615325927734, -0.07241396605968475, -0.005572167225182056, -0.0073489174246788025, -0.1771765947341919, -0.0036804843693971634, 0.21117006242275238], "changes": {"1wk": -21.619612475222002}}, {"text": "Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference Anavex Life Sciences Corp. Mon, Jan 6, 2025, 3:30 PM 3 min read In This Article: AVXL -6.80% Anavex Life Sciences Corp. NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16 th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM \u2013 09:40 AM (Pacific Time). An audio webcast will be accessible through the Investors section of the Company\u2019s website at www.anavex.com . A replay of the session will be available later that day. About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX \u00ae 2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX \u00ae 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX \u00ae 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX \u00ae 2-73 for the treatment of Parkinson's disease. We believe that ANAVEX \u00ae 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX \u00ae 3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn . Story Continues Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors: Andrew J. Barwicki Investor Relations Tel: 516-662-9461 Email: andrew@barwicki.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2025-01-06T12:30:00+00:00", "sentiment": {"score": 0.12690166104584932, "confidence": 0.1365261673927307, "probabilities": {"positive": 0.1365261673927307, "negative": 0.00962450634688139, "neutral": 0.8538493514060974}}, "embedding": [-0.08175548911094666, -0.1082816869020462, -0.030333466827869415, -0.05477073788642883, -0.03736717626452446, -0.002618156373500824, -0.06037452816963196, 0.12396561354398727, 0.15025591850280762, 0.076162189245224, -0.1722218096256256, 0.08918550610542297, 0.057155027985572815, 0.11007833480834961, -0.11762428283691406, 0.030634025111794472, -0.13595235347747803, 0.05699987709522247, 0.07613079994916916, 0.14561493694782257, 0.04969196021556854, -0.04720894992351532, 0.03667251765727997, 0.001469646580517292, -0.065421462059021, 0.08724331110715866, -0.04063820093870163, -0.040444038808345795, -0.17542478442192078, -0.016341179609298706, 0.13003209233283997, 0.13679873943328857, -0.0056173549965023994, -0.12996557354927063, -0.021764542907476425, 0.06357026845216751, -0.11367914080619812, -0.048015207052230835, -0.18528535962104797, -0.10157360136508942, -0.10602130740880966, 0.0027560824528336525, -0.07978278398513794, 0.07170592248439789, 0.037706851959228516, -0.2318500578403473, -0.035368841141462326, -0.08414022624492645, 0.13661780953407288, 0.12904049456119537, -0.09510914981365204, -0.17876723408699036, 0.03225896507501602, 0.09980964660644531, -0.009235924109816551, 0.23722824454307556, -0.22644641995429993, -0.040506478399038315, 0.011262094601988792, -0.052328795194625854, -0.006893564015626907, -0.04550952464342117, 0.05116376280784607, -0.01257559098303318, 0.04352331534028053, 0.09719592332839966, -0.05604265630245209, -0.07071142643690109, -0.044424038380384445, -0.10323771834373474, -0.015510332770645618, -0.12482760846614838, -0.020492741838097572, 0.17552800476551056, 0.06328177452087402, 0.10774605721235275, 0.13048997521400452, 0.026425912976264954, 0.11872932314872742, -0.21024271845817566, 0.06561305373907089, 0.06925585120916367, 0.04954928159713745, 0.1251974254846573, 0.11205042898654938, 0.071311816573143, 0.08862254023551941, 0.08474909514188766, 0.10247544944286346, -0.0071841999888420105, 0.0021272683516144753, 0.020697275176644325, 0.007769566960632801, -0.08544442057609558, 0.03211739659309387, -0.15336889028549194, -0.054042261093854904, 0.16219297051429749, 0.0450403168797493, -0.0024904925376176834, 0.09637513756752014, 0.06462155282497406, -0.0903855562210083, -0.021043317392468452, -0.10282436013221741, -0.019520845264196396, 0.06438064575195312, -0.013186981901526451, 0.09074169397354126, 0.0029236935079097748, -0.1567162275314331, 0.09834682196378708, 0.09594723582267761, -0.031112423166632652, -0.04699312895536423, 0.17150533199310303, -0.057836275547742844, -0.016398048028349876, 0.19464729726314545, -0.05923321843147278, 0.12923774123191833, -0.04218210279941559, 0.028880544006824493, -0.13479721546173096, 0.18810662627220154, 0.03205418959259987, -0.14304952323436737, 8.992528845054622e-33, -0.20747238397598267, -0.0002009752206504345, 0.014407842420041561, 0.1488499492406845, -0.008849399164319038, -0.035342343151569366, 0.07662798464298248, -0.03936581686139107, -0.08439179509878159, -0.1844952404499054, -0.2285504937171936, 0.07061132788658142, 0.040629252791404724, 0.20061302185058594, -0.09613776206970215, -0.013868899084627628, -0.03278299793601036, -0.03573846071958542, -0.024245578795671463, -0.0243813619017601, -0.04788842797279358, 0.023662101477384567, 0.005569724831730127, 0.09751451015472412, 0.010885161347687244, -0.03399164229631424, -0.08297170698642731, 0.09420078247785568, 0.1706542819738388, 0.007872309535741806, -0.013445015996694565, 0.07511963695287704, -0.0629831999540329, -0.06674595177173615, -0.1799076497554779, 0.12486278265714645, 0.00010097399353981018, -0.0539829283952713, 0.0025953231379389763, 0.052577897906303406, 0.05113866552710533, 0.1775514781475067, -0.11094848811626434, -0.031187528744339943, 0.0011561030987650156, -0.0017333123832941055, -0.04488208144903183, 0.039688196033239365, 0.0989285409450531, -0.05206650495529175, 0.04124786704778671, -0.01683487556874752, -0.034124068915843964, -0.06328324228525162, 0.006313355639576912, 0.05213239789009094, -0.1463499218225479, 0.005887112580239773, 0.060354020446538925, 0.12900882959365845, 0.05688024312257767, 0.09693345427513123, 0.017140338197350502, 0.07642949372529984, 0.023736633360385895, 0.11017604917287827, 0.07436972856521606, -0.1335311084985733, -0.05304113030433655, 0.08160985261201859, 0.0119570791721344, 0.12681341171264648, 0.2048366516828537, -0.05298967659473419, 0.09533809870481491, -0.07293163239955902, 0.03559937700629234, 0.0166162196546793, -0.07740730047225952, -0.04626583680510521, -0.017775211483240128, -0.09255451709032059, -0.016110550612211227, 0.17143100500106812, 0.11487491428852081, -0.115764319896698, -0.007362534757703543, 0.037452854216098785, -0.16491954028606415, -0.00671008275821805, 0.09237520396709442, -0.11879977583885193, -0.011421587318181992, 0.14226901531219482, -0.12315279245376587, -7.582774633160777e-33, -0.17063602805137634, -0.009430544450879097, -0.0874025821685791, -0.056649938225746155, -0.09826117753982544, 0.10336141288280487, 0.08324992656707764, -0.03545869514346123, 0.1300639808177948, -0.21300143003463745, 0.15996801853179932, 0.053745757788419724, 0.06330086290836334, 0.017355816438794136, -0.008627022616565228, -0.001921586925163865, -0.09478725492954254, -0.12943041324615479, -0.12108823657035828, 0.02786261960864067, -0.02561003714799881, 0.2662200629711151, -0.09516830742359161, 0.05758282542228699, 0.1401151418685913, 0.0709463432431221, 0.09242577850818634, 0.10891534388065338, 0.03247824311256409, -0.0820700079202652, -0.09372319281101227, 0.04038982093334198, -0.2276538908481598, 0.011923014186322689, 0.036807600408792496, 0.05078650638461113, 0.05430757626891136, -0.21710580587387085, -0.09994320571422577, -0.15299227833747864, 0.06050460785627365, 0.0515473335981369, -0.05449703335762024, -0.10672791302204132, 0.00896446406841278, 0.029817070811986923, 0.0028933901339769363, 0.03074234537780285, 0.08362671732902527, 0.022601792588829994, -0.04300530254840851, -0.1156478002667427, -0.02067968249320984, -0.04493056982755661, 0.023701781406998634, -0.04735651984810829, -0.13364557921886444, -0.07926677912473679, -0.039890408515930176, -0.03043779358267784, -0.017287086695432663, 0.11426906287670135, 0.044164612889289856, 0.0034399572759866714, 0.07600288093090057, 0.11065462231636047, 0.08100443333387375, 0.14282777905464172, -0.011830069124698639, -0.046562228351831436, 0.01317679788917303, 0.08008714765310287, 0.017244286835193634, 0.07457586377859116, 0.043320558965206146, 0.06646919250488281, -0.008107591420412064, -0.10787734389305115, -0.11510756611824036, -0.06221623346209526, -0.03191053122282028, -0.01111617311835289, -0.04293614625930786, 0.10913096368312836, 0.04400380700826645, 0.039913758635520935, -0.06870640814304352, -0.00820639356970787, 0.04281903803348541, 0.010254893451929092, -0.0090921800583601, -0.15210306644439697, -0.09481462836265564, 0.10139630734920502, -0.010036472231149673, -9.96610509673701e-08, 0.13178926706314087, -0.118309885263443, 0.008970956318080425, -0.11648038774728775, 0.037043340504169464, -0.052200667560100555, -0.01691749319434166, 0.008407190442085266, -0.03206279128789902, 0.1520194113254547, 0.13205765187740326, 0.13509009778499603, -0.036360882222652435, -0.009248998947441578, -0.1610647439956665, 0.046070002019405365, -0.046594880521297455, 0.13474425673484802, -0.07476034760475159, -0.13124144077301025, -0.1797201931476593, 0.07158363610506058, 0.03177384287118912, 0.014719204045832157, 0.17020921409130096, -0.22005560994148254, 0.07529078423976898, 0.02209775522351265, 0.0067613995634019375, -0.2252798080444336, -0.11457982659339905, 0.04220578074455261, 0.09726150333881378, 0.06668350100517273, -0.014883235096931458, -0.18169566988945007, 0.009563528001308441, 0.27140012383461, 0.05740805342793465, 0.13229641318321228, 0.042030349373817444, -0.07861530780792236, 0.03954007104039192, -0.03358766436576843, -0.06538709253072739, -0.023229602724313736, -0.10128973424434662, -0.05313713103532791, 0.1355300098657608, -0.16144338250160217, -0.03067370131611824, 0.06982778012752533, 0.04952944070100784, -0.14036452770233154, -0.14021527767181396, 0.14553460478782654, -0.09512467682361603, -0.024382324889302254, 0.11894809454679489, -0.15308907628059387, 0.03307420387864113, 0.02735711634159088, 0.13403135538101196, 0.07002843916416168], "changes": {"1wk": -14.340199570359161}}, {"text": "All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy Zacks Equity Research Mon, Dec 30, 2024, 8:00 PM 3 min read In This Article: AVXL -6.80% Anavex Life Sciences (AVXL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time. Therefore, the Zacks rating upgrade for Anavex Life Sciences basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock. Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Anavex Life Sciences imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher. Harnessing the Power of Earnings Estimate Revisions As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions. The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>. Story Continues Earnings Estimate Revisions for Anavex Life Sciences This biopharmaceutical company is expected to earn -$0.73 per share for the fiscal year ending September 2025, which represents a year-over-year change of -40.4%. Analysts have been steadily raising their estimates for Anavex Life Sciences. Over the past three months, the Zacks Consensus Estimate for the company has increased 8.8%. Bottom Line Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term. You can learn more about the Zacks Rank here >>> The upgrade of Anavex Life Sciences to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2024-12-30T17:00:12+00:00", "sentiment": {"score": 0.1436374019831419, "confidence": 0.16820254921913147, "probabilities": {"positive": 0.16820254921913147, "negative": 0.02456514723598957, "neutral": 0.8072323203086853}}, "embedding": [-0.09915576875209808, -0.01571204513311386, 0.005297712981700897, 0.07748182862997055, 0.0481259748339653, -0.0046112495474517345, -0.06777312606573105, -0.006720933131873608, 0.23999181389808655, 0.14807312190532684, -0.12247182428836823, 0.0949934720993042, 0.04120310768485069, 0.06311386078596115, -0.15819460153579712, -0.056720346212387085, 0.026316218078136444, -0.03423826023936272, -0.14592869579792023, 0.06531000137329102, -0.02239663153886795, -0.13532932102680206, 0.10384790599346161, -0.014428878203034401, 0.05491998791694641, -0.08469238132238388, -0.04971518740057945, 0.12206381559371948, -0.1496962606906891, -0.11772812902927399, -0.08965936303138733, 0.1405082792043686, 0.149435356259346, -0.0922565832734108, -0.22061002254486084, -0.04863102734088898, 0.04801962524652481, 0.04685816168785095, 0.08267204463481903, 0.03802981600165367, -0.08196212351322174, 0.07521365582942963, -0.10225115716457367, -0.01729711890220642, -0.08455353230237961, -0.20085954666137695, 0.02440844476222992, -0.15157364308834076, 0.026645401492714882, 0.07510412484407425, -0.24567067623138428, -0.11973577737808228, 0.06791830062866211, -0.13755404949188232, -0.13075396418571472, 0.16435009241104126, -0.04708847776055336, -0.060689911246299744, 0.11239057779312134, -0.01862574741244316, 0.050783269107341766, 0.03180685639381409, -0.02163228578865528, 0.033542826771736145, 0.157461479306221, -0.032040923833847046, 0.023944199085235596, 0.07338440418243408, -0.10377024114131927, 0.045885223895311356, 0.010428408160805702, -0.06562894582748413, -0.08255788683891296, -0.011653054505586624, 0.007428203709423542, 0.09400661289691925, 0.05410314351320267, 0.01599719002842903, 0.14397427439689636, -0.13465571403503418, 0.0001791892573237419, -0.06633482873439789, -0.05452080816030502, -0.04937291145324707, 0.049219921231269836, -0.0437401607632637, 0.1431150734424591, -0.05185355618596077, 0.08983151614665985, 0.08087919652462006, 0.032529283314943314, -0.08015792071819305, 0.0014453111216425896, -0.029766634106636047, 0.15546566247940063, 0.021551091223955154, -0.1351856142282486, -0.0037071332335472107, 0.019529098644852638, 0.049053750932216644, 0.09756379574537277, 0.028949102386832237, -0.07200262695550919, 0.05305797606706619, 0.02850162237882614, -0.14199553430080414, 0.06831216812133789, -0.023255042731761932, 0.05113854259252548, 0.04180033504962921, -0.05966997519135475, 0.08999602496623993, -0.03648194298148155, -0.08571071177721024, -0.04038513824343681, 0.07139674574136734, -0.06433363258838654, 0.06040152907371521, 0.09383130073547363, 0.05154819041490555, 0.16353316605091095, -0.01915346458554268, 0.03374104201793671, -0.0583246685564518, 0.09101949632167816, 0.0693860799074173, -0.12194482237100601, 1.0970617677839751e-32, -0.000558946281671524, 0.0677298977971077, 0.005873467307537794, 0.07230593264102936, -0.12456953525543213, -0.07652315497398376, -0.008515195921063423, -0.03062823973596096, 0.01394086703658104, -0.10756665468215942, -0.0925687700510025, 0.26560163497924805, 0.009536370635032654, 0.03291726112365723, 0.07887095212936401, -0.028052184730768204, -0.06500785797834396, 0.03270094096660614, -0.025903766974806786, 0.05713234096765518, 0.01108394842594862, -0.05465564876794815, -0.0042257849127054214, -0.09064307808876038, 0.049172159284353256, -0.09007380902767181, -0.04184301942586899, 0.044692039489746094, -0.19179511070251465, 0.028725337237119675, 0.10726413130760193, 0.04792226105928421, -0.016090139746665955, -0.10439549386501312, -0.09053556621074677, -0.05276595056056976, 0.015373286791145802, -0.01587912254035473, 0.13618803024291992, 0.012121148407459259, -0.02448982186615467, 0.07430016249418259, -0.1338045597076416, -0.011685602366924286, -0.06948063522577286, 0.1520596742630005, -0.08686640858650208, 0.04828762263059616, -0.07159432768821716, -0.006732047535479069, -0.0008100774139165878, -0.0016330350190401077, 0.027411827817559242, -0.053425826132297516, -0.06634677946567535, 0.07990558445453644, 0.021992968395352364, -0.13892105221748352, -0.036205895245075226, 0.024197883903980255, -0.023059099912643433, 0.19087743759155273, 0.07358188182115555, -0.030077338218688965, -0.0794326514005661, 0.19085098803043365, 0.0035127466544508934, 0.008636155165731907, -0.0473930761218071, 0.13880732655525208, -0.05124017223715782, 0.13702484965324402, 0.10533491522073746, -0.10197815299034119, 0.028553945943713188, -0.06563761085271835, -0.16743016242980957, -0.022104885429143906, 0.07050789892673492, 0.02135632559657097, -0.014455885626375675, -0.061060525476932526, 0.07783769071102142, -0.10334989428520203, 0.0910860002040863, -0.04763004183769226, -0.015512462705373764, 0.08362998068332672, -0.0007058549672365189, -0.04818849265575409, 0.097257599234581, -0.08482737839221954, -0.04301241785287857, 0.10855794697999954, 0.010568501427769661, -9.984321346834218e-33, -0.191852405667305, -0.04053589329123497, -0.1100677102804184, 0.08444511890411377, -0.07767001539468765, 0.013469732366502285, -0.026968931779265404, 0.040064141154289246, 0.014949552714824677, -0.13029539585113525, -0.004846721887588501, 0.06720900535583496, -0.045948393642902374, 0.014727884903550148, 0.0399361327290535, -0.09071756899356842, -0.03740047290921211, -0.1601540595293045, -0.014027130790054798, -0.05943286418914795, -3.976421430706978e-05, 0.21114304661750793, -0.08831655979156494, 0.10461974889039993, 0.0924912765622139, 0.030275724828243256, -0.016363758593797684, 0.15678103268146515, 0.06667998433113098, -0.11294052004814148, -0.021226948127150536, 0.0077814338728785515, -0.10499829053878784, 0.10079288482666016, 0.010361718013882637, 0.028979187831282616, 0.09918186068534851, -0.2215023636817932, -0.08113600313663483, 0.06498361378908157, 0.05487348139286041, 0.06223270297050476, 0.05658319219946861, -0.1011364534497261, 0.04391039162874222, 0.05841536819934845, 0.06231159716844559, 0.006226811092346907, 0.09362509101629257, -0.024097757413983345, 0.06996177136898041, 0.0351175032556057, 0.017441265285015106, 0.1548474133014679, -0.10673373937606812, -0.001978500746190548, -0.0975373238325119, 0.04620074853301048, -0.045329004526138306, 0.1196315586566925, 0.028736574575304985, 0.19042521715164185, 0.07769839465618134, 0.09850284457206726, -0.028221867978572845, 0.04265918210148811, -0.02177337557077408, -0.0508572980761528, -0.05594529211521149, -0.01042185164988041, 0.055694710463285446, -0.10226672142744064, 0.0531376488506794, -0.024844199419021606, -0.023886194452643394, 0.09596014767885208, 0.03460456430912018, -0.14833669364452362, -0.11269393563270569, -0.056839004158973694, -0.05880636349320412, 0.05336964875459671, 0.029177265241742134, -0.0025019440799951553, -0.06640716642141342, 0.09851806610822678, -0.05103953927755356, 0.006160048767924309, 0.0025885673239827156, -0.11880805343389511, -0.015030112117528915, -0.228304922580719, -0.16243010759353638, -0.07491675019264221, -0.04965271055698395, -9.980148263366573e-08, 0.024788295850157738, -0.06044568866491318, 0.028480684384703636, 0.05854008346796036, 0.09706710278987885, -0.01588757336139679, -0.0017937291413545609, -0.021763863041996956, 0.14552320539951324, 0.08159314841032028, 0.18771439790725708, 0.08704753965139389, -0.09529998898506165, 0.04180534929037094, -0.06733159720897675, -0.018262695521116257, -0.02894327975809574, 0.12295407056808472, -0.03356681019067764, -0.14100980758666992, -0.029624685645103455, 0.04798801243305206, 0.10095708072185516, -0.03453274071216583, 0.1546749770641327, -0.0815838873386383, -0.018312672153115273, -0.0339101180434227, 0.050695061683654785, 0.03174867480993271, 0.008415229618549347, -0.03894323855638504, 0.08412748575210571, 0.09135007858276367, 0.053177278488874435, 0.03256749361753464, 0.08506730943918228, 0.11550520360469818, 0.029769130051136017, 0.19977185130119324, 0.016004353761672974, -0.04489836096763611, -0.10559067130088806, 0.023602182045578957, -0.047476790845394135, -0.014065664261579514, -0.16030070185661316, -0.048489198088645935, 0.10031065344810486, -0.1699259877204895, 0.10544966161251068, -0.02089773118495941, -0.018205510452389717, 0.023493975400924683, -0.048326294869184494, 0.0363454595208168, -0.09737862646579742, -0.006913432851433754, -0.06269140541553497, 0.04558660835027695, 0.1528581976890564, -0.14599427580833435, -0.0057320669293403625, 0.12690502405166626], "changes": {"1wk": 18.749997300514266, "1mo": -12.13768258349682}}, {"text": "Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year? Zacks Equity Research Tue, Dec 31, 2024, 5:40 PM 2 min read In This Article: AVXL -6.80% ABBV +3.39% The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Anavex Life Sciences (AVXL) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Anavex Life Sciences is a member of the Medical sector. This group includes 1020 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Anavex Life Sciences is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for AVXL's full-year earnings has moved 8.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the most recent data, AVXL has returned 18.6% so far this year. In comparison, Medical companies have returned an average of -5.2%. This shows that Anavex Life Sciences is outperforming its peers so far this year. AbbVie (ABBV) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 13.7%. Over the past three months, AbbVie's consensus EPS estimate for the current year has increased 0.9%. The stock currently has a Zacks Rank #2 (Buy). Breaking things down more, Anavex Life Sciences is a member of the Medical - Biomedical and Genetics industry, which includes 501 individual companies and currently sits at #59 in the Zacks Industry Rank. Stocks in this group have lost about 13.1% so far this year, so AVXL is performing better this group in terms of year-to-date returns. In contrast, AbbVie falls under the Large Cap Pharmaceuticals industry. Currently, this industry has 12 stocks and is ranked #141. Since the beginning of the year, the industry has moved +1.8%. Anavex Life Sciences and AbbVie could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2024-12-31T14:40:12+00:00", "sentiment": {"score": 0.8368490971624851, "confidence": 0.8871946334838867, "probabilities": {"positive": 0.8871946334838867, "negative": 0.050345536321401596, "neutral": 0.062459856271743774}}, "embedding": [-0.05894108861684799, -0.13878385722637177, -0.015673188492655754, 0.03276427835226059, -0.032788556069135666, -0.027467401698231697, -0.044515740126371384, 0.039148345589637756, 0.15149950981140137, 0.09293795377016068, -0.1941344141960144, 0.13568858802318573, 0.02231236919760704, -0.020468955859541893, -0.1780019998550415, -0.05801992863416672, -0.04070302098989487, -0.14353066682815552, -0.1132839024066925, 0.13199880719184875, -0.07462529838085175, -0.10746686160564423, 0.11220329999923706, -0.005440557841211557, 0.07364271581172943, -0.0188712440431118, -0.05050382390618324, 0.02242819219827652, -0.1771523654460907, -0.13231047987937927, 0.003927325364202261, 0.1638007014989853, 0.1624518483877182, -0.1264118254184723, -0.18764005601406097, 0.009340310469269753, -0.014473551884293556, 0.00873612891882658, 0.06042924523353577, 0.05581783130764961, -0.0007171060424298048, 0.06185596436262131, -0.06061259284615517, 0.01405105460435152, -0.023699745535850525, -0.2047414481639862, 0.006090380251407623, -0.15717914700508118, 0.1510440707206726, 0.08925619721412659, -0.24798162281513214, -0.1360473334789276, 0.037693023681640625, 0.04352090507745743, -0.14250260591506958, 0.11626306921243668, -0.1926960051059723, -0.16375523805618286, 0.029535342007875443, -0.04788710176944733, 0.17263981699943542, 0.10559810698032379, 0.0675634890794754, 0.06906672567129135, 0.09840838611125946, -0.01280290074646473, 0.001154420431703329, -0.0045755887404084206, -0.07889468222856522, 0.03693661466240883, 0.07205520570278168, -0.15571372210979462, -0.07987421751022339, 0.16535316407680511, -0.01671447977423668, 0.1173052191734314, 0.12169434130191803, 0.013639369048178196, 0.16589000821113586, -0.15668514370918274, 0.05394061654806137, -0.0978221446275711, -0.06956258416175842, -0.021326567977666855, -0.03483084961771965, -0.023959901183843613, 0.1669016182422638, 0.0033896639943122864, 0.014329005032777786, -0.0037658624351024628, 0.11005447804927826, -0.0249415785074234, 0.09883401542901993, -0.03780052065849304, 0.1755761355161667, 0.049242839217185974, -0.042642951011657715, -0.021105919033288956, -0.031550709158182144, 0.05027841031551361, 0.11061765253543854, 0.0857061892747879, -0.0424906350672245, -0.0015849736519157887, -0.09313761442899704, -0.21719413995742798, 0.08499661087989807, -0.01549902930855751, 0.10123970359563828, 0.04056791961193085, -0.08095458894968033, 0.2220619022846222, -0.0795043408870697, -0.036667242646217346, -0.0950048416852951, 0.16106322407722473, -0.04140099883079529, 0.040241584181785583, 0.15998563170433044, 0.07369135320186615, 0.0851149782538414, 0.08275990188121796, 0.06879974156618118, -0.05288439244031906, 0.18968504667282104, 0.037631552666425705, -0.1791629046201706, 9.317508952018829e-33, -0.031006600707769394, 0.05238540098071098, 0.03793305158615112, 0.04187697917222977, -0.18924766778945923, -0.0051930565387010574, 0.038561947643756866, -0.10029043257236481, -0.0914578065276146, -0.16990607976913452, -0.26024121046066284, 0.17520052194595337, 0.05469904839992523, 0.009437206201255322, 0.07058343291282654, -0.03753945231437683, -0.14100012183189392, -0.012896634638309479, -0.05397103726863861, 0.017415281385183334, 0.029083970934152603, 0.020052634179592133, -0.06539574265480042, 0.03728369623422623, -0.005677823442965746, -0.163097083568573, -0.09119029343128204, 0.020462293177843094, -0.15360130369663239, 0.04948490858078003, 0.07724864780902863, 0.07957760989665985, -0.03217613324522972, -0.10257357358932495, -0.06836458295583725, -0.046209871768951416, -0.021773498505353928, 0.06055910140275955, 0.17300286889076233, 0.03092677891254425, -0.11306245625019073, 0.124849334359169, -0.07970258593559265, -0.04477543383836746, 0.024366676807403564, 0.12056076526641846, -0.10444556176662445, 0.014733855612576008, -0.04312993958592415, -0.04814481735229492, -0.07158094644546509, 0.019933806732296944, 0.09907490760087967, -0.032992806285619736, -0.0023008640855550766, 0.12656046450138092, -0.018679460510611534, -0.019556302577257156, -0.04374368488788605, 0.12973414361476898, 0.13408160209655762, 0.234679713845253, 0.09874801337718964, -0.02634960412979126, -0.11218909919261932, 0.14649039506912231, 0.09813697636127472, -0.04160358011722565, -0.06232372298836708, 0.15809118747711182, -0.03507781773805618, 0.09289224445819855, 0.160795196890831, -0.08562883734703064, 0.060881126672029495, -0.028236959129571915, -0.10437814891338348, -0.0793541893362999, -0.015854571014642715, -0.008453987538814545, 0.0199151448905468, -0.0716106966137886, 0.03080865927040577, -0.01936282031238079, 0.051921546459198, -0.14223378896713257, -0.0073471697978675365, 0.010651454329490662, -0.03960955888032913, -0.014356328174471855, -0.044604137539863586, -0.04706306383013725, -0.013636614196002483, 0.06225336715579033, -0.009111807681620121, -8.213389883494502e-33, -0.09004177898168564, -0.05113305151462555, -0.035712335258722305, 0.0628201812505722, -0.07211388647556305, 0.03172383829951286, 0.17287713289260864, 0.10056982934474945, -0.040685586631298065, -0.03561859577894211, 0.12721608579158783, 0.15050949156284332, 0.0027451738715171814, 0.01939023658633232, 0.04484439268708229, -0.008873644284904003, 0.036533474922180176, -0.17986249923706055, -0.011711541563272476, -0.11542834341526031, 0.003747166134417057, 0.19924268126487732, -0.11764241755008698, 0.14785201847553253, 0.09669323265552521, 0.11443446576595306, -0.034190788865089417, 0.1580190509557724, 0.023923657834529877, -0.17290358245372772, -0.0648992583155632, 0.054887086153030396, -0.061650462448596954, 0.0559329017996788, -0.028732258826494217, 0.054025646299123764, 0.0184255950152874, -0.24004539847373962, -0.0968405231833458, -0.11429563164710999, 0.1092912033200264, 0.07716180384159088, -0.019149426370859146, -0.09997378289699554, 0.13107624650001526, 0.003341388888657093, 0.032033853232860565, 0.02172580361366272, 0.13588504493236542, 0.017893444746732712, -0.04420187324285507, -0.01919548213481903, -0.010896454565227032, 0.1410353183746338, -0.015200947411358356, 0.022691510617733, -0.21892845630645752, 0.006244393531233072, -0.20580148696899414, 0.020066343247890472, 0.056679144501686096, 0.19244500994682312, 0.08641783148050308, 0.0691157877445221, -0.06418364495038986, 0.07561735808849335, 0.028255341574549675, 0.023599080741405487, -0.11191979795694351, -0.06996865570545197, 0.10077950358390808, -0.06776624172925949, -0.04527321085333824, -0.04402509331703186, 0.018077855929732323, 0.2712034583091736, 0.028266053646802902, -0.14398464560508728, -0.1514056921005249, -0.03021063283085823, 0.008712198585271835, 0.048551589250564575, 0.03294616565108299, 0.0943911224603653, -0.13815373182296753, 0.20342949032783508, -0.027015548199415207, -0.1592412143945694, -0.010788269340991974, -0.047243595123291016, -0.02175387181341648, -0.25429320335388184, -0.09558862447738647, -0.08351891487836838, 0.020471014082431793, -9.987354587792652e-08, 0.0724867731332779, -0.08131718635559082, 0.09200884401798248, -0.05073169246315956, 0.06296227872371674, -0.07286016643047333, -0.037028633058071136, 0.05497874319553375, 0.13092990219593048, 0.1558839976787567, 0.13478954136371613, 0.014132659882307053, -0.20306864380836487, 0.057555221021175385, -0.06981933116912842, 0.07176695764064789, -0.16891998052597046, 0.1176113411784172, -0.04109088331460953, -0.23102863132953644, -0.045675888657569885, 0.052550315856933594, 0.17919978499412537, 0.028489742428064346, 0.12995468080043793, -0.031001508235931396, -0.04004611074924469, -0.13110584020614624, 0.08028942346572876, 0.017663849517703056, -0.02036052569746971, -0.09510171413421631, 0.09830716252326965, 0.05358709394931793, -0.021425871178507805, -0.0802253931760788, 0.06785452365875244, 0.07849770784378052, 0.022791938856244087, 0.19004718959331512, 0.0802178680896759, -0.08944694697856903, 0.004019467160105705, -0.016196155920624733, 0.03403132036328316, -0.07641814649105072, -0.06921156495809555, -0.04753802716732025, 0.22938001155853271, -0.29478728771209717, 0.0904662013053894, -0.09638829529285431, -0.05354910343885422, 0.02077915146946907, -0.10434126853942871, 0.09513586759567261, -0.16434159874916077, -0.03449459746479988, -0.07930787652730942, 0.01338256150484085, 0.07203378528356552, -0.15977241098880768, 0.07679734379053116, 0.2001127302646637], "changes": {"1wk": 25.325887569787387, "1mo": -10.893855691135961}}, {"text": "Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability TipRanks Thu, Dec 26, 2024, 9:00 AM 1 min read In This Article: AVXL -6.80% https://www.tipranks.com/news/the-fly/charles-river-downgraded-to-market-perform-from-outperform-at-william-blair-2 Anavex Life Sciences ( AVXL ) has disclosed a new risk, in the Manufacturing category. Don't Miss Our Christmas Offers: Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Anavex Life Sciences faces potential risks associated with material modifications in the manufacturing methods of its product candidates. As these candidates transition from preclinical studies to commercialization, changes in manufacturing techniques can lead to increased costs, delays, and the necessity for additional studies. Such alterations may cause variations in product performance, impacting clinical trials and possibly delaying regulatory approval. These challenges could ultimately hinder Anavex\u2019s ability to successfully bring its products to market, affecting its financial stability and operational timelines. The average AVXL stock price target is $27.50, implying 152.99% upside potential. To learn more about Anavex Life Sciences\u2019 risk factors, click here . Trending Articles Disney (NYSE:DIS) Called Out by Trump FCC Ford (NYSE:F) Electric Vehicles May Have Tougher Chassis Soon Can Intel (NASDAQ:INTC) Come Back in 2025? View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "AVXL", "date": "2024-12-26T06:00:06+00:00", "sentiment": {"score": -0.20003043487668037, "confidence": 0.23731005191802979, "probabilities": {"positive": 0.03727961704134941, "negative": 0.23731005191802979, "neutral": 0.7254103422164917}}, "embedding": [-0.09268833696842194, -0.08286147564649582, 0.07790419459342957, 0.053425129503011703, 0.12082099169492722, -0.03171660006046295, 0.010541691444814205, 0.08479751646518707, 0.029956698417663574, 0.08109091222286224, -0.13699114322662354, 0.12591132521629333, 0.061613522469997406, 0.026019250974059105, -0.11855379492044449, -0.05433104187250137, -0.007367538753896952, -0.13739433884620667, -0.12435457855463028, 0.16285984218120575, -0.028781037777662277, -0.11934038251638412, -0.02834208682179451, 0.01652194745838642, -0.048156432807445526, -0.009617151692509651, -0.009564035572111607, 0.024146268144249916, -0.15605518221855164, -0.15012335777282715, -0.06229700520634651, 0.16082380712032318, 0.0462963730096817, -0.11999904364347458, -0.01273254118859768, -0.015303246676921844, 0.012379416264593601, -0.02187654934823513, 0.00990461278706789, -0.09863705188035965, -0.03199845924973488, -0.08512719720602036, -0.14789986610412598, 0.059746429324150085, -0.006669403053820133, -0.19273310899734497, 0.09885142743587494, -0.18529236316680908, 0.11548903584480286, 0.06503269821405411, -0.23058730363845825, -0.11615726351737976, 0.07828910648822784, -0.16088247299194336, -0.0984816625714302, 0.0765191912651062, -0.11600293219089508, -0.11719520390033722, 0.01865864358842373, 0.013821525499224663, 0.1148931086063385, -0.09223823994398117, -0.0006116924341768026, -0.007022272329777479, 0.075449638068676, -0.05328809842467308, 0.04524137079715729, -0.029010137543082237, -0.09167221933603287, 0.1207195371389389, 0.05647262558341026, -0.08113103359937668, -0.12099357694387436, 0.02093946747481823, 0.07133505493402481, 0.14981034398078918, 0.20067521929740906, -0.07408004999160767, 0.16102004051208496, -0.07748352736234665, -0.00207061436958611, -0.010143507272005081, 0.017087558284401894, -0.12055809795856476, 0.0019131439039483666, -0.03532048687338829, 0.1712319552898407, -0.02285158820450306, 0.06368884444236755, 0.00910876039415598, 0.0844046100974083, -0.05589275434613228, 0.048401396721601486, 0.016710635274648666, 0.2047102153301239, 0.04659252241253853, -0.07206529378890991, 0.02646343596279621, 0.012902422808110714, -0.05353299528360367, 0.15076906979084015, 0.045730412006378174, 0.010632200166583061, 0.054463550448417664, -0.129118412733078, -0.17083360254764557, 0.008441069163382053, -0.05637025460600853, 0.025863967835903168, 0.033150747418403625, -0.06885600835084915, 0.07964060455560684, -0.010953187011182308, -0.00468361796811223, -0.13677559792995453, 0.1015479564666748, -0.1185840517282486, -0.09399519115686417, 0.14789129793643951, 0.0014849137514829636, 0.016854045912623405, -0.012254314497113228, 0.050766680389642715, 0.04767318069934845, 0.08985675126314163, 0.055034056305885315, -0.158731147646904, 1.0979090788057272e-32, -0.12438168376684189, -0.00021740140800829977, -0.07197921723127365, 0.03844791650772095, -0.16420942544937134, -0.007788489572703838, 0.046366333961486816, 0.004986641462892294, -0.02095774933695793, -0.0535978339612484, -0.11758068203926086, 0.1092008724808693, -0.03538339212536812, 0.057913344353437424, 0.04039120301604271, -0.0710688903927803, -0.06755952537059784, 0.0010196110233664513, -0.060437124222517014, 0.020998377352952957, -0.005002440419048071, -0.09177042543888092, 0.006992097478359938, -0.011125335469841957, 0.07265159487724304, -0.06697522848844528, 0.008927572518587112, -0.03856734186410904, -0.013727658428251743, 0.0815085619688034, 0.014675349928438663, 0.0942063182592392, 0.03529855236411095, -0.02975858934223652, -0.06236793473362923, 0.06557611376047134, -0.150034561753273, -0.03336024656891823, -0.011467626318335533, 0.03762053698301315, -0.016191285103559494, 0.21888494491577148, 0.0034939951729029417, -0.0012248873244971037, 0.0014898973749950528, 0.08621453493833542, 0.017125459387898445, 0.0032479064539074898, -0.06440376490354538, -0.11614947766065598, -0.13177523016929626, 0.11642441898584366, 0.032972294837236404, -0.10386548936367035, 0.06095883995294571, 0.07356080412864685, 0.0388738177716732, -0.14542657136917114, -0.015543277375400066, 0.11876694858074188, -0.08989158272743225, 0.14747628569602966, 0.06498508900403976, 0.03757356479763985, -0.10802241414785385, 0.2550651431083679, 0.10314303636550903, 0.036715537309646606, -0.1703733652830124, 0.17203876376152039, 0.01805611327290535, -0.02827090583741665, 0.038599513471126556, -0.14134381711483002, 0.10080505162477493, 0.01417299173772335, -0.06550818681716919, -0.07498116046190262, 0.06858609616756439, -0.08208534121513367, -0.036052901297807693, 0.032131679356098175, 0.04836299270391464, -0.0028315866366028786, 0.11811257153749466, -0.1369440257549286, -0.09824281930923462, 0.08130352944135666, -0.04189708083868027, -0.016516804695129395, 0.0714963972568512, -0.05985614284873009, -0.03758104890584946, 0.1336856484413147, -0.05964682251214981, -1.1054351813868669e-32, -0.1239103451371193, -0.10366100817918777, -0.08394330739974976, 0.07905290275812149, -0.09297171235084534, -0.04088553786277771, 0.12989482283592224, 0.01571364514529705, 0.10795359313488007, -0.09481607377529144, 0.012067638337612152, 0.11598577350378036, -0.0020645626354962587, 0.03762061148881912, 0.011652877554297447, -0.064544677734375, -0.016979148611426353, -0.12370985746383667, 0.010609379969537258, -0.08364806324243546, -0.004738915711641312, 0.06174463406205177, -0.10364384949207306, 0.14075061678886414, 0.05506497621536255, 0.061468563973903656, -0.04117559269070625, 0.043156757950782776, 0.04181830212473869, -0.12603743374347687, -0.13953590393066406, -0.005910876207053661, -0.005465461406856775, 0.1328158676624298, 0.0458783358335495, 0.047569941729307175, 0.05210642144083977, -0.1867908388376236, -0.053499456495046616, -0.09170182049274445, 0.0858856737613678, 0.09270621091127396, 0.0563960075378418, -0.08967740088701248, 0.05481511354446411, -0.0046762581914663315, 0.050443850457668304, -0.049210209399461746, 0.20030681788921356, 0.09492729604244232, 0.062399718910455704, -0.044486433267593384, 0.0854741707444191, 0.07193656265735626, -0.10527566820383072, 0.017253614962100983, 0.014755601063370705, 0.023130785673856735, -0.08701509982347488, 0.15375950932502747, 0.0371447317302227, 0.21415169537067413, 0.18363673985004425, -0.04353582113981247, -0.03054969385266304, 0.06041567027568817, -0.03552990406751633, 0.034287307411432266, -0.08580069988965988, -0.15131992101669312, 0.10389018058776855, -0.04944494739174843, -0.06513477861881256, -0.05814558267593384, -0.05754731595516205, 0.07477156817913055, 0.03597775846719742, -0.08984264731407166, -0.03589377924799919, 0.018362442031502724, -0.04684039577841759, 0.07811539620161057, -0.05749387666583061, 0.05722207948565483, 0.01569715514779091, 0.11793017387390137, -0.03958616033196449, -0.015300191938877106, -0.021125392988324165, 0.01602659374475479, -0.016006041318178177, -0.11270399391651154, -0.08989305794239044, 0.12747816741466522, -0.09169690310955048, -1.0000107408814074e-07, 0.03575287386775017, -0.07268109917640686, 0.09365503489971161, -0.03319195657968521, 0.0995066836476326, -0.0644255131483078, -0.022290028631687164, 0.015778597444295883, 0.14461393654346466, 0.1772121638059616, 0.19578765332698822, 0.047094348818063736, -0.05135320872068405, 0.07377965748310089, -0.10535028576850891, 0.07131228595972061, -0.1312497854232788, 0.10103124380111694, -0.04182305186986923, -0.15974314510822296, -0.044055599719285965, 0.07140428572893143, 0.16347990930080414, 0.060581088066101074, 0.04525086656212807, -0.060490697622299194, 0.0105033153668046, 0.00888780690729618, 0.10143154114484787, -0.019890720024704933, -0.203182190656662, -0.047174639999866486, 0.12055270373821259, 0.06537646800279617, -0.05386852100491524, -0.0797206312417984, 0.027851564809679985, 0.1115008220076561, 0.035295482724905014, 0.09336733818054199, 0.03849269077181816, -0.09360267221927643, -0.021908314898610115, -0.0687326043844223, 0.05682353302836418, -0.015050648711621761, -0.21703730523586273, -0.11439827084541321, 0.11149590462446213, -0.0717732235789299, -0.029635801911354065, -0.013729080557823181, 0.0017518341774120927, 0.12879678606987, 0.037235062569379807, 0.07430358231067657, -0.1525653898715973, -0.0403846874833107, 0.01923714019358158, 0.03544992581009865, 0.04793256148695946, -0.24964748322963715, 0.073429174721241, 0.18276898562908173], "changes": {"1wk": -14.49045053896644, "1mo": -16.480896332340304}}]